{{noteTA|G1 = ME}}
{{medical}}
{{Infobox medical condition (new)
| image           = Blue circle for diabetes.svg
| caption         = 空心蓝圈為糖尿病的國際象徵符號<ref>{{Cite web |title=Diabetes Blue Circle Symbol |url=http://www.diabetesbluecircle.org |date=2006-03-17 |publisher=International Diabetes Federation |dead-url=yes |archive-date=2007-08-05 |archive-url=https://web.archive.org/web/20070805042346/http://www.diabetesbluecircle.org/ |accessdate=2017-06-12 }}</ref>
| field           = [[內分泌學|內分泌學]]
| synonyms        = 非胰島素依賴型糖尿病（Noninsulin-dependent diabetes mellitus，NIDDM）<br>成人糖尿病（adult-onset diabetes）<ref name=WHO2015/>
| pronounce       = {{IPAc-en|d|aɪ|ə|b|iː|t|iː|s}}
| symptoms        = [[煩渴|煩渴]]、[[多尿症|多尿症]]、不明原因[[體重下降|體重下降]]、[[多食症|多食症]]<ref name=NIH2014Diag/>
| complications   = [[高渗性高血糖状态|高渗性高血糖状态]]、[[糖尿病酮症酸中毒|糖尿病酮症酸中毒]]、[[心血管疾病|心血管疾病]]、[[中風|中風]]、[[糖尿病视网膜病变|糖尿病视网膜病变]]、[[腎功能衰竭|腎功能衰竭]]、[[截肢|截肢]]<ref name=WHO2015/><ref name=Pas2014/><ref name=Fas2008/>
| onset           = 中年或老年<ref name=NIH2014Cause/>
| duration        = 終身<ref name=NIH2014Cause/>
| causes          = [[肥胖症|肥胖症]]、缺乏運動、[[遺傳|遺傳]]<ref name=WHO2015/><ref name=NIH2014Cause/>
| risks           = 
| diagnosis       = 血糖測量<ref name=NIH2014Diag/>
| differential    = 
| prevention      = 維持正常體重、[[體能鍛煉|體能鍛煉]]、均衡飲食<ref name=WHO2015/>
| treatment       = {{tsl|en|diabetic diet|糖尿病飲食|飲食調整}}、[[二甲双胍|二甲双胍]]、胰島素、[[减肥手术|代謝手術]]<ref name=WHO2015/><ref name=Ann2016/><ref name=Cet2015/><ref name=Kre2005/>
| medication      = 
| prognosis       = [[预期寿命|预期寿命]]縮短約10年<ref name=Will2011/>
| frequency       = 3.92億（2015年）<ref name=GBD2015Pre>{{cite journal|last1=GBD 2015 Disease and Injury Incidence and Prevalence|first1=Collaborators.|title=Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015.|journal=The Lancet|date=2016-10-08|volume=388|issue=10053|pages=1545–1602|pmid=27733282|doi=10.1016/S0140-6736(16)31678-6|pmc=5055577}}</ref>
| deaths          = 
}}

<!-- 定義及症狀 -->
'''第2型糖尿病'''（Type 2 diabetes 或 Type 2 diabetes mellitus，简称 '''T2D''' 或 '''T2DM'''，或称-{zh-cn:'''第2型糖尿病'''; zh-tw: '''2型糖尿病'''}-）{{NoteTag|1=對於本條目名稱的用詞解釋：自從1997年，美國糖尿病學會(ADA)與世界衛生組織(WHO)的專家共同開會決定糖尿病的重新命名，廢棄了原來的 NIDDM、誤用的Type II（羅馬數字），而指定使用 Type 2（阿拉伯數字）。主要是由於醫學的新進展以及避免混淆（Type II 近似 Type 11，eleven）；並且不使用「Diabetes mellitus Type 2」而是使用「Type 2 diabetes mellitus」（T2DM，其後簡稱T2D）。臺灣國健署及糖尿病學會亦使用「第2型」，非「第二型」，而且不用「第II型」；順序亦有規定：「第2型糖尿病」，非「糖尿病第2型」。參考來源見討論頁。}}，旧称'''非胰岛素依赖型糖尿病'''（{{lang-en|noninsulin-dependent diabetes mellitus}}，NIDDM）或'''成人发病型糖尿病'''（{{lang-en|adult-onset diabetes}}），是一种慢性[[代謝疾病|代謝疾病]]，患者特徵為[[高血糖|高血糖]]、相對缺乏[[胰島素|胰島素]]、有[[胰島素抗性|胰島素抗性]]等<ref name="NIH2014Cause">{{Cite news|url=https://www.niddk.nih.gov/health-information/diabetes/overview/symptoms-causes|title=Symptoms & Causes of Diabetes|author=|date=2016-11|work=|newspaper=|accessdate=2017-12-16|language=|website=National Institute of Diabetes and Digestive and Kidney Diseases|archive-date=2021-01-13|archive-url=https://web.archive.org/web/20210113045701/https://www.niddk.nih.gov/health-information/diabetes/overview/symptoms-causes|dead-url=no}}</ref>。常見症狀有[[煩渴|煩渴]]、[[多尿症|頻尿]]、不明原因的[[體重減輕|體重減輕]]<ref name=NIH2014Diag/> ，可能還包括[[多食症|多食]]、疲倦、或有治不好的痠痛<ref name=NIH2014Diag/>，以上症狀通常會慢慢出現<ref name=NIH2014Cause/>。高血糖帶來的長期併發症包括[[心臟病|心臟病]]、[[中風|中風]]、[[糖尿病視網膜病變|糖尿病視網膜病變]]，這可能導致[[失明|失明]]、[[腎功能衰竭|腎臟衰竭]]、甚至四肢血流不順而需要[[截肢|截肢]]<ref name=WHO2015>{{cite web |title=Diabetes Fact sheet N°312 |url=http://www.who.int/mediacentre/factsheets/fs312/en/ |website=World Health Organization |accessdate=2012-01-09 |date=August 2011 |deadurl=yes |archiveurl=https://web.archive.org/web/20130826174444/http://www.who.int/mediacentre/factsheets/fs312/en/ |archivedate=2013-08-26 }}</ref>
；第2型糖尿病患者可能突然發生[[高渗性高血糖状态|高渗性高血糖状态]]，但卻不太會併發[[糖尿病酮酸血症|糖尿病酮酸血症]]<ref name=Pas2014>{{cite journal|last1=Pasquel|first1=FJ|last2=Umpierrez|first2=GE|title=Hyperosmolar hyperglycemic state: a historic review of the clinical presentation, diagnosis, and treatment.|url=https://archive.org/details/sim_diabetes-care_2014-11_37_11/page/3124|journal=Diabetes Care|date=November 2014|volume=37|issue=11|pages=3124–31|pmid=25342831|doi=10.2337/dc14-0984|pmc=4207202}}</ref><ref name=Fas2008>{{cite journal|last1=Fasanmade|first1=OA|last2=Odeniyi|first2=IA|last3=Ogbera|first3=AO|title=Diabetic ketoacidosis: diagnosis and management|journal=African Journal of Medicine and Medical Sciences|date=June 2008|volume=37|issue=2|pages=99–105|pmid=18939392}}</ref>。

<!-- 病因及診斷 -->
第2型糖尿病主要發生在[[肥胖|肥胖]]而又缺乏運動的人<ref name=WHO2015/>，具有先天基因遺傳者風險也較高<ref name=NIH2014Cause/>。2型糖尿病佔了[[糖尿病|糖尿病]]患者約九成的病例，另外一成為[[1型糖尿病|1型糖尿病]]及[[妊娠糖尿病|妊娠糖尿病]]患者<ref name=WHO2015/>。一型糖尿病患者因[[胰臟|胰臟]][[胰島B細胞|β細胞]]遭[[自體免疫|自體免疫]]破壞，而有絕對性胰島素缺乏的問題<ref>{{cite book|editor1-last=MacKay|editor1-first=Ian|editor2-last=Rose|editor2-first=Noel|title=The Autoimmune Diseases| publisher=Academic Press| isbn=978-0-123-84929-8| year=2014| page=575 |oclc=965646175 }}</ref><ref name=Green2011>{{cite book|editor2-last=Shoback |editor1-first=David G. |editor1-last=Gardner |editor2-first=Dolores|title=Greenspan's basic & clinical endocrinology|year=2011|publisher=McGraw-Hill Medical|location=New York|isbn=0-07-162243-8|chapter=Chapter 17: Pancreatic hormones & diabetes mellitus |edition=9th |oclc=613429053 }}</ref>。糖尿病確診需經由血液檢查而定，如檢測{{tsl|en|fasting plasma glucose|空腹血糖值}}、[[口服葡萄糖耐量試驗|口服葡萄糖耐量試驗]]（OGTT）或檢測[[糖化血紅蛋白|糖化血紅蛋白]]（HbA<sub>1c</sub>）<ref name="NIH2014Diag">{{Cite news|url=https://www.niddk.nih.gov/health-information/diabetes/overview/tests-diagnosis|title=Diabetes Tests & Diagnosis|author=|date=|work=|newspaper=National Institute of Diabetes and Digestive and Kidney Diseases|accessdate=2017-12-16|language=|archive-date=2020-05-13|archive-url=https://web.archive.org/web/20200513054120/https://www.niddk.nih.gov/health-information/diabetes/overview/tests-diagnosis|dead-url=no}}</ref>。

<!-- 預防及治療 -->
部分的第2型糖尿病可經由保持正常體重、規律[[運動|運動]]及適當飲食來預防<ref name="WHO2015" />，治療方式有運動和{{le|糖尿病飲食|Diabetic diet|改變飲食}}等<ref name="WHO2015" />。如果沒有經常性血糖偏低，建議的治療藥物選擇包含：雙胍類<ref name="Ann2016">{{cite journal|title=Diabetes Medications as Monotherapy or Metformin-Based Combination Therapy for Type 2 Diabetes: A Systematic Review and Meta-analysis|first1=NM|last2=Tseng|first2=E|date=2016-04-19|journal=Annals of Internal Medicine|doi=10.7326/M15-2650|volume=164|pages=740–51|pmid=27088241|last3=Hutfless|first3=S|last4=Wilson|first4=LM|last5=Suarez-Cuervo|first5=C|last6=Berger|first6=Z|last7=Chu|first7=Y|last8=Iyoha|first8=E|last9=Segal|first9=JB|subscription=yes|first10=S|last10=Bolen|last1=Maruthur}}</ref><ref name="Fer005">{{cite journal|title=Metformin monotherapy for type 2 diabetes mellitus.|first1=A|last2=Fernandez-Esteban|first2=I|date=2005-07-20|journal=Cochrane Database of Systematic Reviews|issue=3|doi=10.1002/14651858.CD002966.pub3|pages=CD002966|pmid=16034881|last3=Mataix|first3=A|last4=Ausejo|first4=M|last5=Roque|first5=M|last6=Moher|first6=D|subscription=yes|name-list-format=vanc|last1=Saenz}}</ref>、[[磺酰脲类|磺醯脲類]]（sulfonylureas）、[[噻唑烷二酮類|噻唑烷二酮類]]（thiazolidinedione）、[[胰高血糖素样肽-1类似物|GLP-1類似物]]、[[二肽基肽酶-4抑制剂|DPP-4抑制劑]]、[[钠-葡萄糖协同转运蛋白2抑制剂|SGLT2抑制劑]]及複方藥物、胰島素，但許多患者最終都必須使用胰島素治療<ref name="Kre2005">{{cite journal|last1=Krentz|first1=Andrew J. |last2=Bailey|first2=Clifford J. |name-list-format=vanc|title=Oral antidiabetic agents: current role in type 2 diabetes mellitus.|journal=Drugs|date=February 2005|volume=65|issue=3|pages=385–411|doi=10.2165/00003495-200565030-00005|pmid=15669880 |subscription=yes}}</ref>。使用胰島素的患者必須定期測量血糖，口服降血糖藥的患者則不一定需要<ref>{{cite journal|last1=Malanda|first1=UL|last2=Welschen|first2=LM|last3=Riphagen|first3=II|last4=Dekker|first4=JM|last5=Nijpels|first5=G|last6=Bot|first6=SD |name-list-format=vanc |title=Self-monitoring of blood glucose in patients with type 2 diabetes mellitus who are not using insulin.|journal=Cochrane Database of Systematic Reviews|date=2012-01-18|volume=1|pages=CD005060|pmid=22258959|doi=10.1002/14651858.CD005060.pub3 |subscription=yes }}</ref>。對肥胖的患者而言，接受[[减肥手术|减肥手术]]對改善糖尿病亦十分有效<ref name="Cet2015">{{cite journal|last1=Cetinkunar|first1=S|last2=Erdem|first2=H|last3=Aktimur|first3=R|last4=Sozen|first4=S|title=Effect of bariatric surgery on humoral control of metabolic derangements in obese patients with type 2 diabetes mellitus: How it works.|journal=World Journal of Clinical Cases|date=2015-06-16|volume=3|issue=6|pages=504–9|doi=10.12998/wjcc.v3.i6.504|pmc=4468896|pmid=26090370}}</ref><ref>{{cite journal|last1=Ganguly|first1=S|last2=Tan|first2=HC|last3=Lee|first3=PC|last4=Tham|first4=KW|title=Metabolic bariatric surgery and type 2 diabetes mellitus: an endocrinologist's perspective.|journal=The Journal of Biomedical Research|date=April 2015|volume=29|issue=2|pages=105–11|doi=10.7555/JBR.29.20140127|pmc=4389109|pmid=25859264}}</ref>。

<!--流行病學及歷史 -->
自1960年起，第2型糖尿病病例就隨著肥胖率逐漸升高<ref>{{cite book |last=Moscou |first=Susan |chapter=Getting the word out: advocacy, social marketing, and policy development and enforcement |editor2-last=Lewenson|editor1-first=Marie |editor1-last=Truglio-Londrigan |editor2-first=Sandra B.|title=Public health nursing: practicing population-based care|date=2013|publisher=Jones & Bartlett Learning|location=Burlington, MA |isbn=978-1-4496-4660-8 |page=[https://books.google.com/books?id=kgA8xfbxIRwC&pg=PA317 317] |edition=2nd |oclc=758391750 }}</ref>。1985年時全球僅有約3000萬人罹患糖尿病，到了2015年患者增至3.92億人<ref name=GBD2015Pre/><ref name=Epi2006>{{cite journal|last1=Smyth|first1=S|last2=Heron|first2=A|title=Diabetes and obesity: the twin epidemics|journal=Nature Medicine|date=January 2006|volume=12|issue=1|pages=75–80|pmid=16397575|doi=10.1038/nm0106-75 |subscription=yes }}</ref>。糖尿病好發於中高齡層<ref name=NIH2014Cause/>，但現今青年人罹患2型糖尿病的比率逐漸增加<ref>{{cite journal|last1=Tfayli|first1=H|last2=Arslanian|first2=S|title=Pathophysiology of type 2 diabetes mellitus in youth: the evolving chameleon |journal=Arquivos Brasileiros de Endocrinologia & Metabologia|date=March 2009|volume=53|issue=2|pages=165–74|doi=10.1590/s0004-27302009000200008|pmc=2846552|pmid=19466209}}</ref><ref>{{Cite journal|last=Imperatore|first=Giuseppina|last2=Boyle|first2=James P.|last3=Thompson|first3=Theodore J.|last4=Case|first4=Doug|last5=Dabelea|first5=Dana|last6=Hamman|first6=Richard F.|last7=Lawrence|first7=Jean M.|last8=Liese|first8=Angela D.|last9=Liu|first9=Lenna L.|date=December 2012|title=Projections of Type 1 and Type 2 Diabetes Burden in the U.S. Population Aged <20 Years Through 2050|url=http://care.diabetesjournals.org/content/35/12/2515|journal=Diabetes Care|language=en|volume=35|issue=12|pages=2515–2520|doi=10.2337/dc12-0669|issn=0149-5992|pmc=3507562|pmid=23173134|deadurl=no|archiveurl=https://web.archive.org/web/20160814110408/http://care.diabetesjournals.org/content/35/12/2515|archivedate=2016-08-14|access-date=2017-12-16}}</ref>。第2型糖尿病患者可能減損長達約十年的壽命<ref name=Will2011>{{cite book |editor1-first=Shlomo |editor1-last=Melmed |editor2-first=Kenneth S. |editor2-last=Polonsky |editor3-first=P. Reed |editor3-last=Larsen |editor4-first=Henry M. |editor4-last=Kronenberg |title=Williams textbook of endocrinology.|year=2011 |url=https://archive.org/details/williamstextbook00melm_993 |publisher=Elsevier/Saunders|location=Philadelphia|isbn=978-1-4377-0324-5|pages=[https://archive.org/details/williamstextbook00melm_993/page/n1365 1371]–1435|edition=12th}}</ref>。糖尿病是最早被描述的疾病之一<ref name=Rip2011>{{cite book |chapter=Diabetes |last2=Ripoll |first1=Brian C. |last1=Leutholtz |first2=Ignacio |title=Exercise and disease management|publisher=CRC Press|location=Boca Raton|isbn=978-1-4398-2759-8|page=[https://books.google.com/books?id=eAn9-bm_pi8C&pg=PA25 25] |edition=2nd|date=2011 |oclc=725919496 }}</ref>，1920年代科學家就發現了胰島素對它的重要性<ref>{{cite journal|last1=Zaccardi|first1=F|last2=Webb|first2=DR|last3=Yates|first3=T|last4=Davies|first4=MJ|name-list-format=vanc|title=Pathophysiology of type 1 and type 2 diabetes mellitus: a 90-year perspective.|journal=Postgraduate Medical Journal|date=February 2016|volume=92|issue=1084|pages=63–9|pmid=26621825|doi=10.1136/postgradmedj-2015-133281 |subscription=yes }}</ref>。

台灣健保資料庫10年追蹤研究發現，65歲以上新確診糖尿病病人，於男性族群之死亡相對風險為非糖尿病患者的1.2倍；於女性族群則為1.27倍。糖尿病患者中，10 年內發生心血管併發症相對風險也高於非糖尿病患者 (8.9%vs.5.8%)，而男性和女性的相對風險分別為1.54及1.70。<ref>{{Cite journal|title=Association of new-onset diabetes mellitus in older people and mortality in Taiwan: A 10-year nationwide population-based study|url=http://dx.doi.org/10.1007/s12603-016-0751-9|last=Chi|first=M.-J.|last2=Liang|first2=C.-K.|date=2016-06-01|journal=The journal of nutrition, health & aging|issue=2|doi=10.1007/s12603-016-0751-9|volume=21|pages=227–232|issn=1279-7707|last3=Lee|first3=W.-J.|last4=Peng|first4=L.-N.|last5=Chou|first5=Ming-Yueh|last6=Chen|first6=Liang-Kung}}</ref>[[File:Diabetes_video.webm|thumb]]
{{TOC limit|3}}

==病征与症状==
[[File:Main_symptoms_of_diabetes.png|thumb]]
糖尿病的典型症状为[[多尿症|多尿症]]、[[煩渴|煩渴]]、[[多食症|多食症]]（{{lang|en|Polyphagia}}）以及[[体重减轻|体重减轻]]<ref name=Vij2010>{{cite journal|last=Vijan|first=S|title=Type 2 diabetes|journal=Annals of Internal Medicine|date=2010-03-02|volume=152|issue=5|pages=ITC31–15; quiz ITC316|doi=10.7326/0003-4819-152-5-201003020-01003|pmid=20194231}}</ref>。诊断时其他常见的症状包括{{tsl|en|blurred vision|視野模糊}}、[[癢|皮肤瘙痒]]、[[周围神经病变|周围神经病变]]、反复[[阴道炎|阴道炎]]、[[疲劳|疲劳]]等病史<ref name=Green2011/>。然而，很多人在最初数年间不会出现病征，一般在常规体检中才被诊断出来<ref name=Green2011/>。在少部分的患者會出現[[高渗性高血糖状态|高渗性高血糖状态]]，此類患者會產生高血糖伴有{{tsl|en|decreased level of consciousness|意识水平下降}}，以及[[低血压|低血压]]的病况<ref name=Green2011/>。

===併发症===
2型糖尿病是慢性疾病，患者的预期寿命可减少長達10年<ref name=Will2011/>。导致预期寿命减少的部分原因是相关的并发症，包括：患上[[心血管疾病|心血管疾病]]的风险是健康人群的二至四倍，其中包括[[冠狀動脈疾病|缺血性心脏病]]及[[中风|中风]]等等。下肢[[截肢|截肢]]率會增加20倍，住院率亦相对增高<ref name=Will2011/>。在发达国家及越来越多的其他地区里，2型糖尿病是导致非创伤性[[失明|失明]]及[[慢性肾病|肾衰竭]]的首要原因<ref name=AFP09/>。在发病过程中，患者罹患{{tsl|en|cognitive dysfunction|认知功能障碍}}及[[失智症|失智症]]风险也会增高，如[[阿兹海默病|阿兹海默病]]及[[血管性痴呆|血管性痴呆]]等等<ref>{{cite journal|last=Pasquier|first=F|title=Diabetes and cognitive impairment: how to evaluate the cognitive status?|journal=Diabetes & Metabolism|date=October 2010|volume=36 Suppl 3|pages=S100–5|doi=10.1016/S1262-3636(10)70475-4|pmid=21211730}}</ref>。其他并发症還包括[[黑棘皮症|黑棘皮症]]、[[性功能障碍|性功能障碍]]，以及容易发生感染<ref name=Vij2010/>。

糖尿病患相較於正常族群會增加2到4倍的心血管疾病風險，約32%的糖友合併有心血管疾病<ref name=":6">{{Cite journal|title=Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007–2017|url=https://cardiab.biomedcentral.com/articles/10.1186/s12933-018-0728-6|last=Einarson|first=Thomas R.|last2=Acs|first2=Annabel|date=2018-12|journal=Cardiovascular Diabetology|issue=1|doi=10.1186/s12933-018-0728-6|volume=17|pages=83|language=en|issn=1475-2840|pmc=PMC5994068|pmid=29884191|last3=Ludwig|first3=Craig|last4=Panton|first4=Ulrik H.|access-date=2021-01-26|archive-date=2021-01-05|archive-url=https://web.archive.org/web/20210105212114/https://cardiab.biomedcentral.com/articles/10.1186/s12933-018-0728-6|dead-url=no}}</ref>，而心血管疾病是全世界糖尿病患者最重要的併發症及主要死因，近6成的糖尿病患者死於心血管疾病。<ref>{{Cite journal|title=Diabetes Mellitus, Fasting Glucose, and Risk of Cause-Specific Death|url=http://dx.doi.org/10.1056/nejmoa1008862|date=2011-03-03|journal=New England Journal of Medicine|issue=9|doi=10.1056/nejmoa1008862|volume=364|pages=829–841|issn=0028-4793}}</ref>

研究顯示，糖化血色素(HbA1c)每增加1％會增加16%心衰竭發生率<ref>{{Cite journal|title=Why are we doing cardiovascular outcome trials in type 2 diabetes?|url=http://dx.doi.org/10.3949/ccjm.81gr.14005|last=MENON|first=V.|last2=AGGARWAL|first2=B.|date=2014-11-01|journal=Cleveland Clinic Journal of Medicine|issue=11|doi=10.3949/ccjm.81gr.14005|volume=81|pages=665–671|issn=0891-1150}}</ref>，近15%的糖友合併有心衰竭<ref name=":6" />，增加60-80%心血管死亡風險。<ref>{{Cite journal|title=PCR testing for diagnosis of Ichthyophonus hoferi: Comment on Hamazaki et al. (2013)|url=http://dx.doi.org/10.3354/dao02681|last=LaPatra|first=SE|last2=Kocan|first2=RM|date=2013-11-06|journal=Diseases of Aquatic Organisms|issue=3|doi=10.3354/dao02681|volume=106|pages=273–274|issn=0177-5103}}</ref><ref>{{Cite journal|title=Graphical Abstract: Chem. Eur. J. 5/2008|url=http://dx.doi.org/10.1002/chem.200890010|date=2008-02-08|journal=Chemistry - A European Journal|issue=5|doi=10.1002/chem.200890010|volume=14|pages=1368–1377|issn=0947-6539}}</ref>男性心衰竭比例高2.5倍，女性心衰竭比例高4.1倍<ref>{{Cite journal|title=Risk of heart failure in a population with type 2 diabetes versus a population without diabetes with and without coronary heart disease|url=http://dx.doi.org/10.1111/dom.13493|last=Chen|first=Hua-Fen|last2=Ho|first2=Ching-An|date=2018-09-04|journal=Diabetes, Obesity and Metabolism|issue=1|doi=10.1111/dom.13493|volume=21|pages=112–119|issn=1462-8902|last3=Li|first3=Chung-Yi}}</ref>，30%-50%心衰竭患者有糖尿病<ref>{{Cite journal|title=Oxygenation of frog gastric mucosa in vitro|url=https://www.ncbi.nlm.nih.gov/pubmed/2018|last=Kidder|first=G. W.|last2=Montgomery|first2=C. W.|date=1975-12|journal=The American Journal of Physiology|issue=6|doi=10.1152/ajplegacy.1975.229.6.1510|volume=229|pages=1510–1513|issn=0002-9513|pmid=2018|access-date=2021-01-26|archive-date=2020-05-18|archive-url=https://web.archive.org/web/20200518013854/https://www.ncbi.nlm.nih.gov/pubmed/2018|dead-url=no}}</ref>，五年存活率僅剩12.5%。另外，約10%的第2型糖尿病患會發生腎病變（約20萬人），40%末期腎臟疾病原因來自於糖尿病。<ref>{{Cite journal|title=Excerpts From the US Renal Data System 2009 Annual Data Report|url=http://dx.doi.org/10.1053/j.ajkd.2009.10.009|last=Collins|first=Allan J.|last2=Foley|first2=Robert N.|date=2010-01|journal=American Journal of Kidney Diseases|issue=1|doi=10.1053/j.ajkd.2009.10.009|volume=55|pages=A6–A7|issn=0272-6386|last3=Herzog|first3=Charles|last4=Chavers|first4=Blanche M.|last5=Gilbertson|first5=David|last6=Ishani|first6=Areef|last7=Kasiske|first7=Bertram L.|last8=Liu|first8=Jiannong|last9=Mau|first9=Lih-Wen}}</ref>

糖尿病血管併發症可分為小血管併發症(Microvascular disease)及大血管併發症(Macrovascular disease)且隨著併發症逐漸加重常會導致患的器官、身體功能的喪失。<ref>{{Cite journal|title=Management of Diabetes in the Elderly|url=http://dx.doi.org/10.1016/j.mcna.2014.11.008|last=Bansal|first=Nidhi|last2=Dhaliwal|first2=Ruban|date=2015-03|journal=Medical Clinics of North America|issue=2|doi=10.1016/j.mcna.2014.11.008|volume=99|pages=351–377|issn=0025-7125|last3=Weinstock|first3=Ruth S.}}</ref>

小血管病變包括視網膜病變、神經病變與腎病變等等，由糖尿病引起的小血管疾病；大血管病變則包括冠狀動脈心臟病（冠心症）、[[中風|中風]]、周邊血管疾病等，糖尿病病患因為常合併患有高血壓、血脂異常及代謝症候群，這些因素也會促進冠狀動脈粥狀硬化的產生<ref>{{Cite web|title=糖尿病心血管疾病|url=https://wd.vghtpe.gov.tw/cv/files/%E7%B3%96%E5%B0%BF%E7%97%85%E5%92%8C%E5%BF%83%E8%A1%80%E7%AE%A1%E7%96%BE%E7%97%85.pdf|access-date=2021-11-26|archive-date=2021-11-26|archive-url=https://web.archive.org/web/20211126074017/https://wd.vghtpe.gov.tw/cv/files/%E7%B3%96%E5%B0%BF%E7%97%85%E5%92%8C%E5%BF%83%E8%A1%80%E7%AE%A1%E7%96%BE%E7%97%85.pdf}}</ref>。

第2型糖尿病人的血脂異常特徵為，三酸甘油脂酯增高、高密度脂蛋白膽固醇下降，低密度脂蛋白膽固醇略上升。<ref name=":5">{{Cite journal|title=Evidence-based diabetes care for older people with Type 2 diabetes: a critical review|url=http://dx.doi.org/10.1111/dme.13859|last=Sinclair|first=A. J.|last2=Abdelhafiz|first2=A. H.|date=2018-11-29|journal=Diabetic Medicine|issue=4|doi=10.1111/dme.13859|volume=36|pages=399–413|issn=0742-3071|last3=Forbes|first3=A.|last4=Munshi|first4=M.}}</ref>高密度脂蛋白膽固醇下降，會增加糖尿病老年患者的心血管疾病及缺血性中風風險。<ref>{{Cite journal|title=Low HDL Cholesterol Is Associated With the Risk of Stroke in Elderly Diabetic Individuals: Changes in the risk for atherosclerotic diseases at various ages|url=http://dx.doi.org/10.2337/dc08-1677|last=Hayashi|first=T.|last2=Kawashima|first2=S.|date=2009-06-09|journal=Diabetes Care|issue=7|doi=10.2337/dc08-1677|volume=32|pages=1221–1223|issn=0149-5992|last3=Itoh|first3=H.|last4=Yamada|first4=N.|last5=Sone|first5=H.|last6=Watanabe|first6=H.|last7=Hattori|first7=Y.|last8=Ohrui|first8=T.|last9=Yokote|first9=K.}}</ref>

另外，高血壓是在糖尿病很常見的共病症，相較於非糖尿病患者族群，糖尿病族群的高血壓發生率可高出1.5–3 倍之多。<ref>{{Cite journal|title=The Treatment of Hypertension in Adult Patients With Diabetes|url=http://dx.doi.org/10.2337/diacare.25.1.134|last=Arauz-Pacheco|first=C.|last2=Parrott|first2=M. A.|date=2002-01-01|journal=Diabetes Care|issue=1|doi=10.2337/diacare.25.1.134|volume=25|pages=134–147|issn=0149-5992|last3=Raskin|first3=P.}}</ref>約有 6–8 成的糖尿病患者死於心血管併發症，而這些心血管併發症的發生有高達 75% 可以歸咎於高血壓所造成。<ref>{{Cite journal|title=Diabetes Mellitus and Associated Hypertension, Vascular Disease, and Nephropathy|url=http://dx.doi.org/10.1161/01.hyp.26.6.869|last=Sowers|first=James R.|last2=Epstein|first2=Murray|date=1995-12|journal=Hypertension|issue=6|doi=10.1161/01.hyp.26.6.869|volume=26|pages=869–879|issn=0194-911X}}</ref>除了心血管併發症，與高血壓相關的糖尿病併發症還包括了腎臟病變、視網膜病變、中風等。<ref name=":5" />

==病因==
第2型糖尿病的發生與患者的生活方式与遗传因素有關<ref name=AFP09/><ref name=Fat2009>{{cite journal |author=Risérus U, [[Walter_Willett|Willett WC]], Hu FB |title=Dietary fats and prevention of type 2 diabetes |journal=Progress in Lipid Research |volume=48 |issue=1 |pages=44–51 |pmid=19032965 |doi=10.1016/j.plipres.2008.10.002 |pmc=2654180|date=January 2009}}</ref>。有些因素如饮食习惯和[[肥胖症|肥胖症]]等是人为可控制的，但其他如年纪增长、性别为女性、遗传等因素则不然<ref name=Will2011/>。睡眠不足也与第2型糖尿病有关<ref name=Sleep2011>{{cite journal|last=Touma|first=C|coauthors=Pannain, S|title=Does lack of sleep cause diabetes?|url=https://archive.org/details/sim_cleveland-clinic-journal-of-medicine_2011-08_78_8/page/549|journal=Cleveland Clinic journal of medicine|date=2011 Aug|volume=78|issue=8|pages=549–58|pmid=21807927|doi=10.3949/ccjm.78a.10165}}</ref>，因為睡眠不足会使致身体的新陈代谢有所改变，進而诱发第2型糖尿病<ref name=Sleep2011/>。孕妇在胎儿发育过程中的营养状况對胎兒未來罹患糖尿病的機率也佔有一席之地，其中[[DNA甲基化|DNA甲基化]]改變是造成此種影響的可能機制之一<ref>{{cite journal|last=Christian|first=P|coauthors=Stewart, CP|title=Maternal micronutrient deficiency, fetal development, and the risk of chronic disease|journal=The Journal of nutrition|date=2010 Mar|volume=140|issue=3|pages=437–45|pmid=20071652|doi=10.3945/jn.109.116327}}</ref>。此外，腸道細菌如腸道{{tsl|en|Prevotella|普氏菌}}（''Prevotella copri''）和普通[[擬桿菌屬|擬桿菌]]（''Bacteroides vulgatus''）也可能和第2型糖尿病有關<ref>{{cite journal|title=Human gut microbes impact host serum metabolome and insulin sensitivity|first1=HK|last2=Gudmundsdottir|first2=V|date=2016-07-21|journal=Nature|issue=7612|doi=10.1038/nature18646|volume=535|pages=376–381|pmid=27409811|last3=Nielsen|first3=HB|last4=Hyotylainen|first4=T|last5=Nielsen|first5=T|last6=Jensen|first6=BA|last7=Forslund|first7=K|last8=Hildebrand|first8=F|last9=Prifti|first9=E|display-authors=3|last1=Pedersen|last10=Falony|first10=G|last11=Le Chatelier|first11=E|last12=Levenez|first12=F|last13=Doré|first13=J|last14=Mattila|first14=I|last15=Plichta|first15=DR|last16=Pöhö|first16=P|last17=Hellgren|first17=LI|last18=Arumugam|first18=M|last19=Sunagawa|first19=S|last20=Vieira-Silva|first20=S|last21=Jørgensen|first21=T|last22=Holm|first22=JB|last23=Trošt|first23=K|author24=MetaHIT Consortium|last25=Kristiansen|first25=K|last26=Brix|first26=S|last27=Raes|first27=J|last28=Wang|first28=J|last29=Hansen|first29=T|last30=Bork|first30=P|last31=Brunak|first31=S|last32=Oresic|first32=M|last33=Ehrlich|first33=SD|last34=Pedersen|first34=O|name-list-format=vanc}}</ref>。

===生活方式===
目前認為有不少生活方式都是引致第2型糖尿病的重要因素，其中包括[[肥胖症|肥胖症]]和[[超重|超重]]（[[身高体重指数|BMI]]高于25）、身體活动量不足、不健康的飲食、压力過大以及[[城市化|城市化]]的生活等<ref name="Will2011" />。30%的華裔與日裔患者體脂過高，欧裔和非裔患者則有60%至80%，印第安人和太平洋岛民患者則100%都體脂過高<ref name="Green2011" />。至於非[[肥胖症|肥胖症]]的第2型糖尿病患則常有過高的[[腰臀比|腰臀比]]<ref name="Green2011" />。吸菸似乎也會增加罹患第2型糖尿病的機會<ref>{{cite journal|title=Relation of active, passive, and quitting smoking with incident type 2 diabetes: a systematic review and meta-analysis.|first1=A|last2=Wang|first2=Y|date=2015-09-17|journal=The Lancet Diabetes & Endocrinology|doi=10.1016/S2213-8587(15)00316-2|volume=3|pages=958–967|pmc=4656094|pmid=26388413|last3=Talaei|first3=M|last4=Hu|first4=FB|last5=Wu|first5=T|last1=Pan}}</ref>。

饮食也是影响第2型糖尿病发病风险的重要因素。饮用过量的含[[糖|糖]]饮料可增加患病风险<ref name="SSB2010">{{cite journal|last=Malik|first=VS|coauthors=Popkin, BM, Bray, GA, Després, JP, Hu, FB|title=Sugar Sweetened Beverages, Obesity, Type 2 Diabetes and Cardiovascular Disease risk|journal=Circulation|date=2010-03-23|volume=121|issue=11|pages=1356–64|pmid=20308626|doi=10.1161/CIRCULATIONAHA.109.876185|pmc=2862465}}</ref><ref>{{cite journal|last=Malik|first=VS|coauthors=Popkin, BM, Bray, GA, Després, JP, Willett, WC, Hu, FB|title=Sugar-Sweetened Beverages and Risk of Metabolic Syndrome and Type 2 Diabetes: A meta-analysis|url=https://archive.org/details/sim_diabetes-care_2010-11_33_11/page/2477|journal=Diabetes Care|date=2010 Nov|volume=33|issue=11|pages=2477–83|pmid=20693348|doi=10.2337/dc10-1079|pmc=2963518}}</ref>。饮食裡摄取的[[脂肪|脂肪]]也是很重要的因素，[[饱和脂肪|饱和脂肪]]与[[反式脂肪|反式脂肪]]均會增加患病风险，而[[多元不饱和脂肪|多元不饱和脂肪]]与[[单元不饱和脂肪|单元不饱和脂肪]]則有助於降低风险<ref name="Fat2009" />。攝取大量[[白米|白米]]似乎也会使致病风险增加<ref>{{cite journal|last=Hu|first=EA|coauthors=Pan, A, Malik, V, Sun, Q|title=White rice consumption and risk of type 2 diabetes: meta-analysis and systematic review|journal=BMJ (Clinical research ed.)|date=2012-03-15|volume=344|pages=e1454|pmid=22422870|doi=10.1136/bmj.e1454|pmc=3307808}}</ref>。也有學者相信，7%的病例可能是缺乏运动所致<ref>{{cite journal|last=Lee|first=I-Min|coauthors=Shiroma, Eric J; Lobelo, Felipe; Puska, Pekka; Blair, Steven N; Katzmarzyk, Peter T|title=Effect of physical inactivity on major non-communicable diseases worldwide: an analysis of burden of disease and life expectancy|journal=The Lancet|date=2012-07-01|doi=10.1016/S0140-6736(12)61031-9}}</ref>。[[持久性有機污染物|持久性有機污染物]]可能也和糖尿病相關<ref>{{cite journal|title=Can persistent organic pollutants and plastic-associated chemicals cause cardiovascular disease?|first1=L|last2=Lind|first2=PM|date=Jun 2012|journal=Journal of Internal Medicine|issue=6|doi=10.1111/j.1365-2796.2012.02536.x|volume=271|pages=537–53|pmid=22372998|last1=Lind}}</ref>。

===遗传因素===
大多数糖尿病个案涉及多種基因，而这些不同的基因都可能会使患上第2型糖尿病的几率上升<ref name=Will2011/>。如果[[同卵雙生|同卵双胞胎]]的其中一人有糖尿病，另一人患上糖尿病的机会高于90%，然而非同卵的兄弟姐妹的几率只有25%至50%<ref name=Green2011/>。到2011年为止，共发现了超过36个[[基因|基因]]都可能增加罹患第2型糖尿病的风险<ref name=Genetic2011>{{cite journal|last=Herder|first=C|coauthors=Roden, M|title=Genetics of type 2 diabetes: pathophysiologic and clinical relevance|journal=European journal of clinical investigation|date=2011 Jun|volume=41|issue=6|pages=679–92|pmid=21198561|doi=10.1111/j.1365-2362.2010.02454.x}}</ref>。然而，即使全部这些基因加在一起，亦只占诱发糖尿病的整体遗传因素中的10%<ref name=Genetic2011/>。舉例來說，可使发病风险增加1.5倍的[[等位基因|等位基因]]{{tsl|en|TCF7L2|TCF7L2}}为常见基因变异中擁有最高风险的基因<ref name=Green2011/>。多数与糖尿病有关的基因都与{{tsl|en|beta cells|β細胞}}功能有关<ref name=Green2011/>。

在一部分罕见的糖尿病个案中，发病原因是因单个基因出现异常而引起的（称为[[遗传性疾病|单基因]]型糖尿病或[[糖尿病#其他类型糖尿病|“其他特殊类型糖尿病”]]）。<ref name=Green2011/><ref name=Will2011/>其中包括{{tsl|en|maturity onset diabetes of the young|年輕人成人型糖尿病}}（简称MODY）、{{tsl|en|Leprechaunis|矮妖精貌综合征}}、{{lang|en|Rabson-Mendenhall}}综合征等等<ref name=Will2011/>。其中年輕人成人型糖尿病占年轻糖尿病患者个案总和的1%至5%<ref>{{cite news|title=Monogenic Forms of Diabetes: Neonatal Diabetes Mellitus and Maturity-onset Diabetes of the Young|date=2007年3月|publisher=National Institute of Diabetes and Digestive and Kidney Diseases, NIH|url=http://www.diabetes.niddk.nih.gov/dm/pubs/mody/|work=National Diabetes Information Clearinghouse (NDIC)|accessdate=2008-08-04|archive-url=https://web.archive.org/web/20080704103703/http://diabetes.niddk.nih.gov/dm/pubs/mody/|archive-date=2008-07-04|dead-url=yes}}</ref>。

===健康状况===
許多药物和健康问题都会使人較易患糖尿病<ref name=BookDM2008>{{cite book|last=Bethel|first=edited by Mark N. Feinglos, M. Angelyn|title=Type 2 diabetes mellitus: an evidence-based approach to practical management|year=2008|publisher=Humana Press|location=Totowa, NJ|isbn=978-1-58829-794-5|page=462|url=http://books.google.ca/books?id=NctBmHUOV7AC&pg=PA462|access-date=2014-03-16|archive-date=2013-10-15|archive-url=https://web.archive.org/web/20131015193109/http://books.google.ca/books?id=NctBmHUOV7AC&pg=PA462|dead-url=no}}</ref>。這些药物包括：[[糖皮质激素|糖皮质激素]]、[[噻嗪类利尿剂|噻嗪类利尿剂]]、[[β受体阻滞剂|β受体阻滞剂]]、{{tsl|en|atypical antipsychotic|非典型抗精神病药物}}<ref>{{cite journal|last=Izzedine|first=H|coauthors=Launay-Vacher, V, Deybach, C, Bourry, E, Barrou, B, Deray, G|title=Drug-induced diabetes mellitus|journal=Expert opinion on drug safety|date=2005 Nov|volume=4|issue=6|pages=1097–109|pmid=16255667|doi=10.1517/14740338.4.6.1097}}</ref>及[[他汀类药物|他汀类药物]]<ref>{{cite journal|last=Sampson|first=UK|coauthors=Linton, MF, Fazio, S|title=Are statins diabetogenic?|journal=Current opinion in cardiology|date=2011 Jul|volume=26|issue=4|pages=342–7|pmid=21499090|doi=10.1097/HCO.0b013e3283470359|pmc=3341610}}</ref>。曾患[[妊娠糖尿病|妊娠糖尿病]]的人患上第2型糖尿病的风险较高<ref name="Vij2010" />，而其他和第2型糖尿病相关的健康问题還包括[[肢端肥大症|肢端肥大症]]、[[皮质醇增多症|皮质醇增多症]]、[[甲状腺功能亢进症|甲状腺功能亢进症]]、{{tsl|en|pheochromocytoma|嗜铬细胞瘤}}及某些[[癌症|癌症]]如{{tsl|en|glucagonoma|胰高血糖素瘤}}<ref name="BookDM2008" />。另外，[[睾酮|睾酮]]缺乏与第2型糖尿病也有很密切的关联<ref name="pmid19444934">{{cite journal |author=Saad F, Gooren L|title=The role of testosterone in the metabolic syndrome: a review |journal=The Journal of Steroid Biochemistry and Molecular Biology |volume=114 |issue=1–2 |pages=40–3 |pmid=19444934|doi=10.1016/j.jsbmb.2008.12.022|date=March 2009}}</ref><ref name="pmid18832284">{{cite journal |author=Farrell JB, Deshmukh A, Baghaie AA |title=Low testosterone and the association with type 2 diabetes |journal=The Diabetes Educator |volume=34 |issue=5|pages=799–806 |year=2008 |pmid=18832284 |doi=10.1177/0145721708323100}}</ref>。

==病理生理学==
第2型糖尿病的病因复杂，对于单一病患而言，难以确认引发疾病的原因，往往环境和遗传因素中的一种或者多种均有可能与发病相关<ref name=":2">{{Cite web|title=Pathogenesis of type 2 diabetes mellitus|url=https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus|accessdate=2019-11-22|author=David K McCulloch; R Paul Robertson,|date=2019-10|format=|publisher=Uptodate|language=|archive-date=2020-12-22|archive-url=https://web.archive.org/web/20201222191742/https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus|dead-url=no}}</ref>。胰岛β细胞功能失常和胰岛素抵抗引发了第2型糖尿病<ref name=":3">{{Cite journal|title=β-cell dysfunction: Its critical role in prevention and management of type 2 diabetes|url=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4317303/|last=Saisho|first=Yoshifumi|date=2015-02-15|journal=World Journal of Diabetes|issue=1|doi=10.4239/wjd.v6.i1.109|volume=6|pages=109–124|issn=1948-9358|pmc=4317303|pmid=25685282|access-date=2019-11-22|archive-date=2021-01-05|archive-url=https://web.archive.org/web/20210105212245/https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4317303/|dead-url=no}}</ref>：尽管在1980年代，人们普遍认为仅靠胰岛素抵抗即可引发糖尿病，但后来的研究表明，在没有β细胞功能失常的情况下，糖尿病不可能发生<ref>{{Cite web|title=Why We Are Fat {{!}} BU Today|url=http://www.bu.edu/articles/2012/why-we-are-fat/|accessdate=2019-12-07|work=Boston University|language=en|archive-date=2021-01-05|archive-url=https://web.archive.org/web/20210105212207/http://www.bu.edu/articles/2012/why-we-are-fat/|dead-url=no}}</ref>。在这两种症状的程度方面，患者表现出的胰岛素抵抗和相对胰岛素不足的程度有所差异：有些人以胰岛素抵抗为主、轻微的胰岛素分泌缺陷为次；而其他人可能只有轻微的胰岛素抵抗，而以胰岛素分泌不足为主<ref name="Green2011" />。

在第2型糖尿病中，胰岛素抵抗和高血浆胰岛素水平的发生往往先于疾病发生<ref name=":2" />：尽管过去曾认为高胰岛素水平是胰岛素抵抗引起的代偿，但后来的研究表明，血浆中的高胰岛素水平不一定是代偿胰岛素抵抗的后果，亦有可能是产生胰岛素抵抗的原因<ref>{{Cite journal|title=Insulin Resistance and Hyperinsulinemia: Is hyperinsulinemia the cart or the horse?|url=https://care.diabetesjournals.org/content/31/Supplement_2/S262|last=Shanik|first=Michael H.|last2=Xu|first2=Yuping|date=2008-02-01|journal=Diabetes Care|issue=Supplement 2|doi=10.2337/dc08-s264|volume=31|pages=S262–S268|language=en|issn=0149-5992|pmid=18227495|last3=Škrha|first3=Jan|last4=Dankner|first4=Rachel|last5=Zick|first5=Yehiel|last6=Roth|first6=Jesse|access-date=2019-12-07|archive-date=2020-12-22|archive-url=https://web.archive.org/web/20201222191801/https://care.diabetesjournals.org/content/31/Supplement_2/S262|dead-url=no}}</ref>。再者，在肥胖诱导的炎症等各种因素作用下，胰岛β细胞的生产或者分泌胰岛素的功能受损。<ref name=":2" />

其他可能与第2型糖尿病和胰岛素抵抗、胰岛功能受损有关的重要机制還包括：[[脂肪细胞|脂肪细胞]]内[[脂质|脂质]]的分解增加、对{{tsl|en|incretin|腸泌素}}的抵抗或缺乏、血液中[[胰高血糖素|胰高血糖素]]水平过高、肾脏积蓄的盐份和水份上升，及[[中枢神经系统|中枢神经系统]]的代谢調節異常<ref name="Will2011" />。

=== 胰岛素抵抗 ===
[[胰岛素抵抗|胰岛素抵抗]]被认为是第2型糖尿病的主要特征之一<ref name=":3" />。在胰岛素抵抗的情况下，应当对胰岛素进行响应的组织或器官（如肌肉、肝脏及脂肪组织）无法对正常濃度的胰岛素作出适当响应<ref>{{cite book|title=Diabetes mellitus a guide to patient care.|year=2007|publisher=Lippincott Williams & Wilkins|location=Philadelphia|isbn=978-1-58255-732-8|page=15|url=http://books.google.ca/books?id=fiAclxvKblkC&pg=PA15|access-date=2014-03-16|archive-date=2013-10-16|archive-url=https://web.archive.org/web/20131016090540/http://books.google.ca/books?id=fiAclxvKblkC&pg=PA15|dead-url=no}}</ref>——例如：具体到肝脏而言，指的是肝脏无法正常响应胰岛素信号，致使糖原分解和葡萄糖异生不能被抑制，血糖被不当增加<ref>{{Cite journal|title=Hepatic insulin resistance, metabolic syndrome and cardiovascular disease|url=http://www.sciencedirect.com/science/article/pii/S0009912009002513|last=Meshkani|first=Reza|last2=Adeli|first2=Khosrow|date=2009-09-01|journal=Clinical Biochemistry|issue=13|doi=10.1016/j.clinbiochem.2009.05.018|volume=42|pages=1331–1346|issn=0009-9120|access-date=2019-11-22|archive-date=2020-08-08|archive-url=https://web.archive.org/web/20200808163744/https://www.sciencedirect.com/science/article/pii/S0009912009002513|dead-url=no}}</ref>；具体到肌肉而言，指的是肌肉组织无法无法正常响应胰岛素信号，致使肌肉吸收的血糖减少，血糖下降变缓<ref>{{Cite journal|title=Skeletal Muscle Insulin Resistance: Roles of Fatty Acid Metabolism and Exercise|url=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2579902/|last=Turcotte|first=Lorraine P|last2=Fisher|first2=Jonathan S|date=2008-11|journal=Physical Therapy|issue=11|doi=10.2522/ptj.20080018|volume=88|pages=1279–1296|issn=0031-9023|pmc=2579902|pmid=18801860|access-date=2019-11-22|archive-date=2021-01-05|archive-url=https://web.archive.org/web/20210105212230/https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2579902/|dead-url=no}}</ref>。并不只有葡萄糖在这一过程受到影响：第2型糖尿病患者的肝脏和肌肉常见异位脂肪沉积，其氧化过程和葡萄糖形成底物竞争，{{Tsl|en|Randle cycle|葡萄糖-脂肪酸循环|抑制了葡萄糖的氧化}}，亦被用来解释胰岛素抵抗的形成。此类的脂肪累积早于第2型糖尿病的发病。<ref name=":4">{{Cite journal|title=Causation of Type 2 Diabetes — The Gordian Knot Unravels|url=https://doi.org/10.1056/NEJMp038239|last=Taylor|first=Roy|date=2004-02-12|journal=New England Journal of Medicine|issue=7|doi=10.1056/NEJMp038239|volume=350|pages=639–641|issn=0028-4793|pmid=14960738}}</ref>

歐洲胰島素阻抗研究組織(EGIR)研究發現胰島素敏感度會依年齡增加而下降，不過兩者關聯性會因身體質量指數（body mass index, BMI）校正而消失。<ref>{{Cite journal|title=Insulin action and age. European Group for the Study of Insulin Resistance (EGIR)|url=http://dx.doi.org/10.2337/diabetes.45.7.947|last=Ferrannini|first=E.|last2=Vichi|first2=S.|date=1996-07-01|journal=Diabetes|issue=7|doi=10.2337/diabetes.45.7.947|volume=45|pages=947–953|issn=0012-1797|last3=Beck-Nielsen|first3=H.|last4=Laakso|first4=M.|last5=Paolisso|first5=G.|last6=Smith|first6=U.}}</ref>老化後胰島素阻抗性的現象可能來自於腹部脂肪組織增生、骨骼肌肉量降低、生理活動減少、粒線體功能不全、荷爾蒙分泌減退、氧化壓力和慢性發炎等。<ref>{{Cite journal|title=Frailty in the elderly is associated with insulin resistance of glucose metabolism in the postabsorptive state only in the presence of increased abdominal fat|url=http://dx.doi.org/10.1016/j.exger.2009.08.008|last=Goulet|first=Eric D.B.|last2=Hassaine|first2=Assia|date=2009-11|journal=Experimental Gerontology|issue=11|doi=10.1016/j.exger.2009.08.008|volume=44|pages=740–744|issn=0531-5565|last3=Dionne|first3=Isabelle J.|last4=Gaudreau|first4=Pierrette|last5=Khalil|first5=Abdelouahed|last6=Fulop|first6=Tamàs|last7=Shatenstein|first7=Bryna|last8=Tessier|first8=Daniel|last9=Morais|first9=José A.}}</ref><ref>{{Cite journal|title=Glucose Intolerance and Aging: Evidence for Tissue Insensitivity to Insulin|url=http://dx.doi.org/10.2337/diab.28.12.1095|last=DeFronzo|first=R. A.|date=1979-12-01|journal=Diabetes|issue=12|doi=10.2337/diab.28.12.1095|volume=28|pages=1095–1101|issn=0012-1797}}</ref>

动物实验显示，单独的胰岛素抵抗并不一定引起糖尿病：消耗大量能量的大脑和肌肉之中存在的胰岛素抵抗并未在引起胰岛素抵抗，有鉴于此，肝脏和胰岛中的胰岛素抵抗可能是借由其它途径诱导。双基因敲除则提示胰岛素抵抗的多基因型，如IRS-1和GK双基因敲除可以诱导小鼠糖尿病，而单基因敲除不能。胰岛素抵抗往往会与高血压、高血脂等心血管风险因子聚集，形成所谓的“[[代谢综合征|代谢综合征]]”。<ref name=":2" />

=== β细胞功能异常 ===
然而，并非所有出现胰岛素抵抗的人士都会患上糖尿病，患者的胰岛β细胞需同時有胰岛素分泌障碍時才会发病<ref name="Green2011" />。胰岛β细胞功能失常是1型糖尿病和2型糖尿病的共同特征之一，但在2型糖尿病中，胰岛功能常常被忽视。2型糖尿病中的β细胞功能下降往往在糖类不耐受发生以前就已经发生<ref name=":3" />。确诊时，胰岛功能通常已经是正常水平的三成左右；英国前瞻性糖尿病研究中显示，胰島的功能衰減無法透過飲食，磺脲類、二甲雙胍或胰島素治療等單一治療手段進行控制。目前用藥選擇中，DPP4i抑制劑、GLP-1類似物觀察到針對第2型糖尿病患者β細胞功能的改善<ref>{{Cite journal|title=Causation of Type 2 Diabetes — The Gordian Knot Unravels|url=https://doi.org/10.1056/NEJMp038239|last=Taylor|first=Roy|date=2004-02-12|journal=New England Journal of Medicine|issue=7|doi=10.1056/NEJMp038239|volume=350|pages=639–641|issn=0028-4793|pmid=14960738}}</ref>。

1型糖尿病的胰岛素分泌不足主要是因为[[自体免疫|自体免疫]]引起的β细胞死亡，而2型糖尿病中的β细胞功能下降或者死亡的原因则较为复杂，与氧化应激、[[炎症|炎症]]等相关<ref name=":3" />。如以脂质毒性的角度而言，在肝脏和肌肉中异位累积的过量脂肪难以被有效氧化，透过非氧化途径生成反应性脂肪，诱导脂质的凋亡亦纠正脂肪过载的情形；在这一过程生成的[[神经酰胺|神经酰胺]]等物质可介导胰腺细胞的衰亡<ref name=":4" />。由于饮食和遗传因素等原因，[[亚洲人|亚裔]]群体，特别是[[印度人口|印度人]]，易于产生在器官内累积大量脂肪的腹部肥胖；尽管亚裔人群较西方群体纤瘦，也有较高的糖尿病流行率可能与之相关<ref>{{Cite journal|title=Abdominal obesity and type 2 diabetes in Asian Indians: dietary strategies including edible oils, cooking practices and sugar intake|url=https://www.nature.com/articles/ejcn201792|last=Gulati|first=S.|last2=Misra|first2=A.|date=2017-07|journal=European Journal of Clinical Nutrition|issue=7|doi=10.1038/ejcn.2017.92|volume=71|pages=850–857|language=en|issn=1476-5640|access-date=2019-11-22|archive-date=2020-11-16|archive-url=https://web.archive.org/web/20201116104928/https://www.nature.com/articles/ejcn201792|dead-url=no}}</ref><ref>{{Cite journal|title=Obesity in Asia – is it different from rest of the world|url=https://onlinelibrary.wiley.com/doi/abs/10.1002/dmrr.2353|last=Ramachandran|first=Ambady|last2=Chamukuttan|first2=Snehalatha|date=2012|journal=Diabetes/Metabolism Research and Reviews|issue=s2|doi=10.1002/dmrr.2353|volume=28|pages=47–51|language=en|issn=1520-7560|last3=Shetty|first3=Samith A.|last4=Arun|first4=Nanditha|last5=Susairaj|first5=Priscilla}}</ref>。但这一过程不仅仅和脂质毒性有关，还和糖类引发的氧化应激有关<ref>{{Cite journal|title=Glucose Toxicity in β-Cells: Type 2 Diabetes, Good Radicals Gone Bad, and the Glutathione Connection|url=https://diabetes.diabetesjournals.org/content/52/3/581|last=Robertson|first=R. Paul|last2=Harmon|first2=Jamie|date=2003-03-01|journal=Diabetes|issue=3|doi=10.2337/diabetes.52.3.581|volume=52|pages=581–587|language=en|issn=0012-1797|pmid=12606496|last3=Tran|first3=Phuong Oanh|last4=Tanaka|first4=Yoshito|last5=Takahashi|first5=Hiroki|access-date=2019-12-07|archive-date=2020-12-22|archive-url=https://web.archive.org/web/20201222191915/https://diabetes.diabetesjournals.org/content/52/3/581|dead-url=no}}</ref>：过量的糖类与脂质在能量循环中会形成竞争，糖类的氧化往往受到抑制<ref>{{Cite journal|title=The Randle cycle revisited: a new head for an old hat|author=|url=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2739696/|last=Hue|first=Louis|last2=Taegtmeyer|first2=Heinrich|date=2009|journal=American Journal of Physiology - Endocrinology and Metabolism|issue=3|doi=10.1152/ajpendo.00093.2009|others=|year=|volume=297|page=|pages=E578–E591|issn=0193-1849|pmc=2739696|pmid=19531645|access-date=2019-12-07|archive-date=2021-01-05|archive-url=https://web.archive.org/web/20210105212350/https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2739696/|dead-url=no}}</ref>。

==诊断==
{{OGTT}}
[[世界卫生组织|世界卫生组织]]定义糖尿病（包括-{zh-tw:第1型; zh-hk:一型; zh-cn:1型;}-和-{zh-tw:第2型; zh-hk:二型; zh-cn:2型;}-）为有症状之单次血糖值上升，或两次血糖值上升達到以下標準<ref name=who-99>{{Cite web |url=http://www.who.int/diabetes/publications/en/ |author=World Health Organization |title=Definition, diagnosis and classification of diabetes mellitus and its complications: Report of a WHO Consultation. Part 1. Diagnosis and classification of diabetes mellitus |accessdate=2007-05-29 |archive-date=2007-05-29 |archive-url=https://web.archive.org/web/20070529092627/http://www.who.int/diabetes/publications/en/ |dead-url=no }}</ref>：
* 空腹血糖≥7.0 mmol/l（126 mg/dl）
: 
* 作出[[糖耐力测试|糖耐力测试]]，口服两小时之后，血糖≥11.1 mmol/l（200 mg/dl）。

随机血糖高于11.1 mmol/l （200 mg/dl ）且出現典型症狀<ref name=Vij2010/>或[[糖化血红蛋白|糖化血红蛋白]]（HbA<sub>1c</sub>）高于6.5%是也一种诊断糖尿病的方法<ref name=Will2011/>。2009年，一个由美国糖尿病协会（{{lang|en|American Diabetes Association}}，简称ADA）、国际糖尿病联合会（{{lang|en|International Diabetes Federation}}，简称IDF）和欧洲糖尿病研究协会（{{lang|en|European Association for the Study of Diabetes}}，简称EASD）之專家代表組成的国际专家委员会建议糖尿病诊断应使用48 mmol/mol作為臨界值（相當於 HbA<sub>1c</sub> 6.5%）<ref name="Expert2009" />，美国糖尿病协会于2010年采用此建议<ref>{{cite journal|title=Diagnosis and classification of diabetes mellitus|journal=Diabetes Care|volume=33 Suppl 1|issue=Supplement_1|pages=S62–9|pmid=20042775|pmc=2797383|doi=10.2337/dc10-S062|publisher=American Diabetes Association|date=January 2010}}</ref>。只有病患出现典型症状和血糖>11.1  mmol/l（>200  mg/dl）才应该重复进行阳性检验<ref name="Expert2009">{{cite journal|last=International Expert|first=Committee|title=International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes|url=https://archive.org/details/sim_diabetes-care_2009-07_32_7/page/1327|journal=Diabetes Care|date=2009 Jul|volume=32|issue=7|pages=1327–34|pmid=19502545|doi=10.2337/dc09-9033|pmc=2699715}}</ref>。

糖尿病診斷之临界阈根據的是糖耐力测试、空腹血糖或HbA<sub>1c</sub>，和并发症（如[[糖尿病視網膜病變|視網膜病變]]）的关系<ref name=Will2011/>。比起糖耐力测试，空腹或随机血糖因为比较方便而被廣泛使用<ref name=Will2011/>。HbA<sub>1c</sub>的优点是不需禁食且结果较稳定，但缺点是检验较血糖测量昂贵<ref>{{cite journal|title=Diagnosis and classification of diabetes mellitus|journal=Diabetes Care|volume=35 Suppl 1|pages=S64–71|date=January 2012|pmid=22187472 |doi=10.2337/dc12-s064 |url= |last1= American Diabetes |first1= Association}}</ref>。估计美國有20%的糖尿患者不知道自己患有糖尿病<ref name=Will2011/>。 

2型糖尿病的特征是在[[胰岛素抵抗|胰岛素抵抗]]或[[胰岛素|胰岛素]]相對缺乏所造成的高血糖<ref name="Pathologic Basis of Disease">{{Cite book | author=Kumar, Vinay; Fausto, Nelson; Abbas, Abul K.; Cotran, Ramzi S. ; Robbins, Stanley L.|title=Robbins and Cotran Pathologic Basis of Disease|year=2005|edition=7th|publisher=Saunders|location=Philadelphia, Pa.|isbn=0-7216-0187-1|pages=1194–1195}}</ref>，这与[[1型糖尿病|1型糖尿病]]中的绝对胰岛素缺乏大不相同，後者是因為[[胰岛|胰岛]]细胞损坏所導致的。而[[妊娠期糖尿病|妊娠期糖尿病]]則是在懷孕時新發生的高血糖<ref name="Green2011"/>。-{zh-tw:第1型; zh-hk:一型; zh-cn:1型;}-和2型糖尿病通常可以根据臨床表現来区分<ref name=Expert2009/>。如果对诊断存在疑问，[[抗体|抗体]]试验可能有助于判定1型糖尿病，{{tsl|en|C-peptide|C-胜肽}}水平则有助于判定2型糖尿病<ref>{{cite book|title=Diabetes mellitus a guide to patient care.|year=2007|publisher=Lippincott Williams & Wilkins|location=Philadelphia|isbn=978-1-58255-732-8|page=201|url=http://books.google.ca/books?id=fiAclxvKblkC&pg=PA201|access-date=2014-03-16|archive-date=2013-10-16|archive-url=https://web.archive.org/web/20131016090544/http://books.google.ca/books?id=fiAclxvKblkC&pg=PA201|dead-url=no}}</ref>。

===臺灣診斷標準===
診斷標準包括以下4項，非懷孕狀況下“只要符合其中1項”即可診斷為糖尿病（前三項需重複驗證2次以上）<ref>{{Cite web |url=https://www.hpa.gov.tw/Pages/List.aspx?nodeid=359 |title=存档副本 |access-date=2021-10-25 |archive-date=2022-03-03 |archive-url=https://web.archive.org/web/20220303151454/https://www.hpa.gov.tw/Pages/List.aspx?nodeid=359 }}</ref>：<br>
(一)  [[糖化血色素|糖化血色素]]（HbA1c）≧ 6.5%<br>
(二)  [[空腹血漿血糖|空腹血漿血糖]] ≧ 126 mg/dL<br>
(三)  [[口服葡萄糖耐受試驗|口服葡萄糖耐受試驗]]的[[第2小時血漿血糖|第2小時血漿血糖]] ≧ 200 mg/dL<br>
(四)  典型的[[高血糖症狀|高血糖症狀]]（多吃、多喝、多尿與體重減輕）且 [[隨機血漿血糖|隨機血漿血糖]] ≧ 200 mg/dL<br>

===中国大陆诊断标准===
[[File:糖尿病的诊断标准.webp|thumb]]
<ref>{{Cite web |url=https://mp.weixin.qq.com/s/_P6kfSxa05IPEIKSyi34kw |title=存档副本 |access-date=2021-10-25 |archive-date=2021-10-27 |archive-url=https://web.archive.org/web/20211027045043/https://mp.weixin.qq.com/s/_P6kfSxa05IPEIKSyi34kw }}</ref>

==筛檢==
由于没有证据证明大規模糖尿病{{tsl|en|Screening (medicine)|篩檢 (醫學)|篩檢}}可改善最终结果，因此没有大型組織或部门建议进行全面篩檢<ref name=Screen09>{{cite journal |author=Valdez R |title=Detecting Undiagnosed Type 2 Diabetes: Family History as a Risk Factor and Screening Tool|journal=Journal of Diabetes Science and Technology|volume=3|issue=4|pages=722–26|year=2009|doi= 10.1177/193229680900300417|pmc=2769984|pmid=20144319}}</ref><ref name=Selph_et_al-2015>{{cite journal|last1=Selph|first1=S|last2=Dana|first2=T|last3=Blazina|first3=I|last4=Bougatsos|first4=C|last5=Patel|first5=H|last6=Chou|first6=R|title=Screening for Type 2 Diabetes Mellitus: A Systematic Review for the U.S. Preventive Services Task Force |journal=Annals of Internal Medicine|date=2015-06-22|volume=162 |issue=11 |pages=765–76|doi=10.7326/M14-2221 |pmid=25867111}}</ref>。{{tsl|en|United States Preventive Services Task Force|美國預防服務任務小組}}（USPSTF）建议对没有症状且[[血压|血压]]高于 135/80 毫米水银柱的成年人进行筛檢<ref name=US08>{{cite web |url=http://www.uspreventiveservicestaskforce.org/uspstf/uspsdiab.htm |title=Archived: Diabetes Mellitus (Type 2) in Adults: Screening |date=June 2008 |work=U.S. Preventive Services Task Force |accessdate=2014-03-16 |deadurl=yes |archiveurl=https://web.archive.org/web/20140207214318/http://www.uspreventiveservicestaskforce.org/uspstf/uspsdiab.htm |archivedate=2014-02-07 }}</ref>。对于血压较低的人，并没有充分证据顯示能夠降低此群體的風險和死亡率<ref name=US08/><ref name=Selph_et_al-2015/>。USPSTF也建議40至70歲之間的過重者進行篩檢<ref>{{cite journal|last1=Siu|first1=AL|title=Screening for Abnormal Blood Glucose and Type 2 Diabetes Mellitus: U.S. Preventive Services Task Force Recommendation Statement|journal=Annals of Internal Medicine|date=2015-10-27|doi=10.7326/M15-2345|volume=163|issue=11|pages=861–68|pmid=26501513}}</ref>。

[[世界卫生组织|世界卫生组织]]（WHO）和USPSTF皆建議高風險者進行篩檢<ref name=Screen09/><ref>{{cite web |title=Draft Recommendation Statement Screening for Abnormal Glucose and Type 2 Diabetes Mellitus |url=http://www.uspreventiveservicestaskforce.org/Page/Document/RecommendationStatementDraft/screening-for-abnormal-glucose-and-type-2-diabetes-mellitus |website=U.S. Preventive Services Task Force |accessdate=2014-10-07 |dead-url=yes |archive-date=2014-10-09 |archive-url=https://web.archive.org/web/20141009152304/http://www.uspreventiveservicestaskforce.org/Page/Document/RecommendationStatementDraft/screening-for-abnormal-glucose-and-type-2-diabetes-mellitus }}</ref>。在美國，高風險者包含年齡超過45歲、{{tsl|en|first degree relative|一等親}}（包含手足）有糖尿病、部分族裔（如拉美裔、非裔，以及美洲原住民）、有[[妊娠糖尿病|妊娠糖尿病]]或[[多囊卵巢綜合症|多囊卵巢綜合症]]病史、過重，或是患有[[代謝症候群|代謝症候群]]等等<ref name="Vij2010" />。{{tsl|en|American Diabetes Association|美國糖尿病學會}}建議BMI超過25者進行篩檢（亞裔則建議23以上就應該篩檢）<ref name=ADA21015>{{cite journal|title=Standards of Medical Care in Diabetes – 2015: Summary of Revisions|journal=Diabetes Care|date=2015|pages=S4|volume=54|issue=38|doi=10.2337/dc15-S003|pmid=25537706}}</ref>。也建議，45 歲以上成人應每 1–3 年檢查一次空腹血糖、HbA1C 或口服葡萄糖耐受試驗。<ref>{{Cite journal|title=Diabetes in Older Adults|url=http://dx.doi.org/10.2337/dc12-1801|last=Kirkman|first=M. S.|last2=Briscoe|first2=V. J.|date=2012-10-25|journal=Diabetes Care|issue=12|doi=10.2337/dc12-1801|volume=35|pages=2650–2664|issn=0149-5992|last3=Clark|first3=N.|last4=Florez|first4=H.|last5=Haas|first5=L. B.|last6=Halter|first6=J. B.|last7=Huang|first7=E. S.|last8=Korytkowski|first8=M. T.|last9=Munshi|first9=M. N.}}</ref>衛生福利部國民健康署亦提供整合性篩檢，篩檢項目也包含糖尿病，40–64 歲的民眾，建議每 3 年篩檢一次；而針對 65 歲以上的民眾，建議每年篩檢一次。<ref>{{Cite web|title=衛生福利部國民健康署，成人預防保健|url=https://www.hpa.gov.tw/Pages/List.aspx?nodeid=189|accessdate=|author=|date=|format=|publisher=|language=|archive-url=https://web.archive.org/web/20201211141705/https://www.hpa.gov.tw/|archive-date=2020-12-11|dead-url=no}}</ref>

==预防==
适当营养和经常运动可以延缓或防止2型糖尿病的发病<ref>{{cite journal|author=Raina Elley C, Kenealy T |title=Lifestyle interventions reduced the long-term risk of diabetes in adults with impaired glucose tolerance|journal=Evid Based Med|volume=13|issue=6|pages=173|pmid=19043031|doi=10.1136/ebm.13.6.173|date=December 2008}}</ref><ref>{{cite journal |author=Orozco LJ, Buchleitner AM, Gimenez-Perez G, Roqué I Figuls M, Richter B, Mauricio D|title=Exercise or exercise and diet for preventing type 2 diabetes mellitus|journal=Cochrane Database Syst Rev|issue=3|pages=CD003054|year=2008|pmid=18646086|doi=10.1002/14651858.CD003054.pub3|editor1-last=Mauricio|editor1-first=Didac}}</ref>，強力的執行生活方式控制可以降低超過一半的風險<ref name=AFP09/><ref name=Schellenberg2013>{{Cite journal | last1 = Schellenberg | first1 = ES. | last2 = Dryden | first2 = DM. | last3 = Vandermeer | first3 = B. | last4 = Ha | first4 = C. | last5 = Korownyk | first5 = C. | title = Lifestyle Interventions for Patients With and at Risk for Type 2 Diabetes: A Systematic Review and Meta-analysis | journal = Annals of Internal Medicine | volume = 159 | issue = 8 | pages = 543–51 |date=October 2013 | doi = 10.7326/0003-4819-159-8-201310150-00007 | pmid = 24126648 }}</ref>。無論原始體重多寡或后来的体重是否减轻，运动皆有益处<ref>{{cite journal|last=O'Gorman|first=DJ|coauthors=Krook, A|title=Exercise and the treatment of diabetes and obesity|journal=The Medical clinics of North America|date=2011 Sep|volume=95|issue=5|pages=953–69|pmid=21855702|doi=10.1016/j.mcna.2011.06.007}}</ref>。但单靠調整饮食便能降低風險的证据卻十分有限<ref>{{cite journal |author=Nield L, Summerbell CD, Hooper L, Whittaker V, Moore H |title=Dietary advice for the prevention of type 2 diabetes mellitus in adults|journal=Cochrane Database Syst Rev|issue=3|pages=CD005102 |year=2008|pmid=18646120|doi=10.1002/14651858.CD005102.pub2|editor1-last=Nield|editor1-first=Lucie}}</ref>，一些证据支持多攝取綠色蔬菜<ref>{{cite journal|last=Carter|first=P|coauthors=Gray, LJ, Troughton, J, Khunti, K, Davies, MJ|title=Fruit and vegetable intake and incidence of type 2 diabetes mellitus: systematic review and meta-analysis|journal=BMJ (Clinical research ed.)|date=2010-08-18|volume=341|pages=c4229|pmid=20724400|doi=10.1136/bmj.c4229|pmc=2924474}}</ref>，也有一些证据支持限制含糖饮料<ref name=SSB2010/>。对于{{tsl|en|impaired fasting glucose|葡萄糖耐受不良}}的人士，只改变饮食习惯和运动，或同時使用[[二甲双胍|二甲双胍]]或[[阿拉伯糖|阿拉伯糖]]，可以降低罹患糖尿病的风险<ref name=AFP09/><ref name=AHRQ05>{{cite journal |author=Santaguida PL, Balion C, Hunt D, ''et al.'' |title=Diagnosis, prognosis, and treatment of impaired glucose tolerance and impaired fasting glucose |journal=Evid Rep Technol Assess (Summ) |issue=128 |pages=1–11 |pmid=16194123 |url=http://www.ahrq.gov/downloads/pub/evidence/pdf/impglucose/impglucose.pdf |format=PDF |date=August 2005 |deadurl=yes |archiveurl=https://web.archive.org/web/20080910035155/http://www.ahrq.gov/downloads/pub/evidence/pdf/impglucose/impglucose.pdf |archivedate=2008-09-10 |access-date=2014-03-16 }}</ref>，改变生活方式比服用二甲双胍还有效<ref name=AFP09/>。一份2017年的回顧文獻指出，長期的生活方式改造能降低28%罹病風險，但糖尿病藥物在停藥後將無助於減低風險<ref>{{cite journal|title=Long-term Sustainability of Diabetes Prevention Approaches: A Systematic Review and Meta-analysis of Randomized Clinical Trials|first1=JS|last2=Galaviz|first2=KI|date=2017-11-06|journal=JAMA Internal Medicine|issue=12|doi=10.1001/jamainternmed.2017.6040|volume=177|pages=1808–17|pmid=29114778|last3=Straus|first3=AN|last4=Kowalski|first4=AJ|last5=Magee|first5=MJ|last6=Weber|first6=MB|last7=Wei|first7=J|last8=Narayan|first8=KMV|last9=Ali|first9=MK|last1=Haw}}</ref>。血中的維生素D含量較低會增加糖尿病的風險，但口服補充維生素D3無法改善罹病風險<ref>{{cite journal|title=Effect of Vitamin D3 Supplementation on Improving Glucose Homeostasis and Preventing Diabetes: A Systematic Review and Meta-Analysis|first1=Jennifer C.|last2=Mitri|first2=Joanna|date=Oct 2014|journal=The Journal of Clinical Endocrinology & Metabolism|issue=10|doi=10.1210/jc.2014-2136|volume=99|pages=3551–60|pmc=4483466|pmid=25062463|last3=Colmers|first3=Isabelle N.|last4=Majumdar|first4=Sumit R.|last5=Davidson|first5=Mayer B.|last6=Edwards|first6=Alun L.|last7=Hanley|first7=David A.|last8=Pittas|first8=Anastassios G.|last9=Tjosvold|first9=Lisa|last1=Seida|last10=Johnson|first10=Jeffrey A.}}</ref>。

==管理==
2型糖尿病的疾病管理着重于調整生活型態、减低其他心血管风险因素，以及將血糖維持在正常值<ref name=AFP09>{{cite journal |vauthors=Ripsin CM, Kang H, Urban RJ |title=Management of blood glucose in type 2 diabetes mellitus |journal=American Family Physician |volume=79 |issue=1 |pages=29–36 |date=January 2009 |pmid=19145963 |doi= |url=}}</ref>。[[國民保健署_(英國)|英国國民保健署]]建议2型糖尿病初诊人士进行血糖自我监测<ref name=NICE2009Self>{{Cite web|title=Type 2 diabetes: The management of type 2 diabetes|url=http://www.nice.org.uk/guidance/cg87/chapter/1-recommendations#self-monitoring-of-plasma-glucose|date=May 2009|deadurl=no|archiveurl=https://web.archive.org/web/20150522055955/http://www.nice.org.uk/guidance/cg87/chapter/1-recommendations#self-monitoring-of-plasma-glucose|archivedate=2015-05-22|accessdate=2018-04-27}}</ref>，但是对于没有使用多剂量胰岛素的人士，自我监测的益处仍有爭議<ref name=AFP09/><ref>{{cite journal|last=Farmer|first=AJ |author2=Perera, R |author3=Ward, A |author4=Heneghan, C |author5=Oke, J |author6=Barnett, AH |author7=Davidson, MB |author8=Guerci, B |author9=Coates, V |author10=Schwedes, U |author11=O'Malley, S|title=Meta-analysis of individual patient data in randomised trials of self monitoring of blood glucose in people with non-insulin treated type 2 diabetes|journal=The BMJ |date=27 February 2012|volume=344|pages=e486|pmid=22371867|doi=10.1136/bmj.e486}}</ref>。管理其他心血管风险因素如[[高血压|高血压]]、[[高膽固醇血症|高胆固醇]]和[[微量白蛋白尿|微量白蛋白尿]]能改善预期餘命<ref name=AFP09/>。將收縮壓控制於 140 mmHg 以下能夠降低死亡風險，並改善預後<ref>{{cite journal|last1=Emdin|first1=CA|last2=Rahimi|first2=K|last3=Neal|first3=B|last4=Callender|first4=T|last5=Perkovic|first5=V|last6=Patel|first6=A|title=Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis|journal=JAMA: the Journal of the American Medical Association|date=10 February 2015|volume=313|issue=6|pages=603–15|pmid=25668264|doi=10.1001/jama.2014.18574}}</ref>，更高積極的血壓管理（低于130/80 mmHg）相較於標準血壓管理（140/85–100 mmHg）雖能使中风风险轻微减低，但对总体死亡风险并没有影响<ref>{{cite journal|last=McBrien|first=K|author2=Rabi, DM |author3=Campbell, N |author4=Barnieh, L |author5=Clement, F |author6=Hemmelgarn, BR |author7=Tonelli, M |author8=Leiter, LA |author9=Klarenbach, SW |author10= Manns, BJ |title=Intensive and Standard Blood Pressure Targets in Patients With Type 2 Diabetes Mellitus: Systematic Review and Meta-analysis|journal=Archives of Internal Medicine|date=6 August 2012|pages=1–8|pmid=22868819|volume=172|issue=17|doi=10.1001/archinternmed.2012.3147}}</ref>。

相对于标准血糖控制（HbA<sub>1C</sub>7-7.9%），更積極的血糖控制（HbA<sub>1C</sub><6%）似乎并未改善死亡率<ref>{{cite journal|last=Boussageon|first=R|author2=Bejan-Angoulvant, T|author3=Saadatian-Elahi, M|author4=Lafont, S|author5=Bergeonneau, C|author6=Kassaï, B|author7=Erpeldinger, S|author8=Wright, JM|author9=Gueyffier, F|author10=Cornu, C|title=Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials|journal=The BMJ |date=2011-07-26|volume=343|pages=d4169|pmid=21791495|doi=10.1136/bmj.d4169|pmc=3144314}}</ref><ref>{{cite journal|last=Webster|first=MW|title=Clinical practice and implications of recent diabetes trials|journal=Current Opinion in Cardiology|date=July 2011|volume=26|issue=4|pages=288–93|pmid=21577100|doi=10.1097/HCO.0b013e328347b139}}</ref>。2型糖尿病的治疗目标通常是HbA<sub>1C</sub>低于7%至8%或空腹血糖低于7.2 mmol/L（130 mg/dl）；但若將[[低血糖症|低血糖症]]和预期餘命等特定风险納入考量，这些目标在专业临床会诊后可以改变<ref name=ADA2015/><ref>{{cite journal|last1=Qaseem|first1=Amir|last2=Wilt|first2=Timothy J.|last3=Kansagara|first3=Devan|last4=Horwitch|first4=Carrie|last5=Barry|first5=Michael J.|last6=Forciea|first6=Mary Ann|title=Hemoglobin A Targets for Glycemic Control With Pharmacologic Therapy for Nonpregnant Adults With Type 2 Diabetes Mellitus: A Guidance Statement Update From the American College of Physicians|journal=Annals of Internal Medicine|date=6 March 2018|doi=10.7326/M17-0939}}</ref>。儘管臨床指引建議醫師須衡量血糖控制的長期好處和立即傷害，許多人仍被過度治療，例如對預期餘命小於9年的患者進行強化血糖控制便沒有好處<ref>{{cite journal|last1=Makam|first1=AN|last2=Nguyen|first2=OK|title=An Evidence-Based Medicine Approach to Antihyperglycemic Therapy in Diabetes Mellitus to Overcome Overtreatment.|journal=Circulation|date=10 January 2017|volume=135|issue=2|pages=180–95|doi=10.1161/CIRCULATIONAHA.116.022622|pmid=28069712}}</ref>。

所有患有2型糖尿病的人士都應定期进行[[眼科|眼科]]检查<ref name="Green2011" />。有限的證據顯示以[[牙結石清除術|刮除牙結石和牙根整平術]]治療[[牙周炎|牙周病]]或許可以短期改善糖尿病患者的血糖<ref name=Simpson2015>{{Cite journal|last=Simpson|first=Terry C.|last2=Weldon|first2=Jo C.|last3=Worthington|first3=Helen V.|last4=Needleman|first4=Ian|last5=Wild|first5=Sarah H.|last6=Moles|first6=David R.|last7=Stevenson|first7=Brian|last8=Furness|first8=Susan|last9=Iheozor-Ejiofor|first9=Zipporah|date=2015-11-06|title=Treatment of periodontal disease for glycaemic control in people with diabetes mellitus|url=|journal=Cochrane Database of Systematic Reviews|volume=|issue=11|pages=CD004714|doi=10.1002/14651858.CD004714.pub3|issn=1469-493X|pmid=26545069|via=}}</ref>，但沒有證據顯示這樣的改善能持續超過4個月<ref name=Simpson2015 />。目前並沒有證據表示治療牙周病的藥物有助於改善血糖<ref name=Simpson2015 />。
===生活方式===
适当的饮食和运动是糖尿病治疗的基础<ref name=Vij2010/>，运动量越充足效果越佳<ref>{{cite journal|last1=Smith|first1=AD|last2=Crippa|first2=A|last3=Woodcock|first3=J|last4=Brage|first4=S|title=Physical activity and incident type 2 diabetes mellitus: a systematic review and dose-response meta-analysis of prospective cohort studies.|journal=Diabetologia|date=December 2016|volume=59|issue=12|pages=2527–45|doi=10.1007/s00125-016-4079-0|pmid=27747395}}</ref>。運動能改善血糖控制，降低體脂和血脂，這些效果即使在沒有體重減輕的情形下也都有證據支持<ref>{{Cite journal|title=Exercise for type 2 diabetes mellitus|last=Thomas|first=D. E.|last2=Elliott|first2=E. J.|date=2006-07-19|journal=The Cochrane Database of Systematic Reviews|issue=3|doi=10.1002/14651858.CD002968.pub2|pages=CD002968|issn=1469-493X|pmid=16855995|last3=Naughton|first3=G. A.}}</ref>。[[有氧运动|有氧运动]]可使HbA<sub>1c</sub>下降并改善胰岛素敏感性<ref name=Exercise10/>。[[力量訓練|阻力训练]]也有改善的效果，若能同時進行有氧運動及阻力训练效果尤佳<ref name=Exercise10>{{cite journal |vauthors=Zanuso S, Jimenez A, Pugliese G, Corigliano G, Balducci S |title=Exercise for the management of type 2 diabetes: a review of the evidence |journal=Acta Diabetologica |volume=47 |issue=1 |pages=15–22 |date=March 2010 |pmid=19495557 |doi=10.1007/s00592-009-0126-3 |url=https://link.springer.com/content/pdf/10.1007%2Fs00592-009-0126-3.pdf |access-date=2018-04-27 |archive-date=2020-12-22 |archive-url=https://web.archive.org/web/20201222192934/https://link.springer.com/content/pdf/10.1007%2Fs00592-009-0126-3.pdf |dead-url=no }}</ref>。

能促進減重的{{tsl|en|diabetic diet|糖尿病饮食|飲食}}調整相當重要<ref name="Diet09" />。目前最理想的飲食配方為何仍有爭議<ref name="Diet09">{{cite journal |vauthors=Davis N, Forbes B, Wylie-Rosett J |title=Nutritional strategies in type 2 diabetes mellitus |journal=Mount Sinai Journal of Medicine |volume=76 |issue=3 |pages=257–68 |date=June 2009 |pmid=19421969 |doi=10.1002/msj.20118 |url=}}</ref>，但目前已知{{le|低升糖指數飲食|low glycemic index diet}}或[[低碳水化合物飲食|低碳水化合物飲食]]可以改善血糖<ref>{{cite journal |author=Thomas D, Elliott EJ |title=Low glycaemic index, or low glycaemic load, diets for diabetes mellitus |journal=Cochrane Database of Systematic Reviews |volume= |issue=1 |pages=CD006296 |year=2009 |pmid=19160276 |doi=10.1002/14651858.CD006296.pub2 |editor1-last=Thomas |editor1-first=Diana}}</ref><ref>{{cite journal|last1=Feinman|first1=RD|last2=Pogozelski|first2=WK|last3=Astrup|first3=A|last4=Bernstein|first4=RK|last5=Fine|first5=EJ|last6=Westman|first6=EC|last7=Accurso|first7=A|last8=Frassetto|first8=L|last9=Gower|first9=BA|last10=McFarlane|first10=SI|last11=Nielsen|first11=JV|last12=Krarup|first12=T|last13=Saslow|first13=L|last14=Roth|first14=KS|last15=Vernon|first15=MC|last16=Volek|first16=JS|last17=Wilshire|first17=GB|last18=Dahlqvist|first18=A|last19=Sundberg|first19=R|last20=Childers|first20=A|last21=Morrison|first21=K|last22=Manninen|first22=AH|last23=Dashti|first23=HM|last24=Wood|first24=RJ|last25=Wortman|first25=J|last26=Worm|first26=N|title=Dietary carbohydrate restriction as the first approach in diabetes management: critical review and evidence base.|journal=Nutrition |location=Burbank, Los Angeles County, Calif.|date=January 2015|volume=31|issue=1|pages=1–13|pmid=25287761|doi=10.1016/j.nut.2014.06.011}}</ref>。在第2型糖尿病發病後短時間內開始{{Internal link helper/en|超低卡路里飲食|Very-low-calorie diet}}能使疾病緩解<ref>{{cite journal|title=Assessing the evidence for weight loss strategies in people with and without type 2 diabetes.|first1=P|date=15 October 2017|journal=World journal of diabetes|issue=10|doi=10.4239/wjd.v8.i10.440|volume=8|pages=440–454|pmid=29085571|last1=Clifton}}</ref>。[[素食主義|素食者]]相對來說罹患糖尿病的機會較低，但葷食攝取適量者效果則與素食無異<ref name="GlickBauerYeh2014">{{cite journal|title=The health advantage of a vegan diet: exploring the gut microbiota connection|journal=Nutrients|issue=11|doi=10.3390/nu6114822|year=2014|volume=6|pages=4822–38|type=Review|pmc=4245565|pmid=25365383|vauthors=Glick-Bauer M, Yeh MC}}</ref>。目前尚無證據支持肉桂可以改善第2型糖尿病患者的血糖<ref>{{Cite journal|title=Cinnamon for diabetes mellitus|last=Leach|first=Matthew J.|last2=Kumar|first2=Saravana|date=2012-09-12|journal=Cochrane Database of Systematic Reviews|issue=9|doi=10.1002/14651858.CD007170.pub2|pages=CD007170|issn=1469-493X|pmid=22972104}}</ref>。

適當的衛教也能協助患者控制血糖，效果最佳可維持到24個月<ref>{{Cite journal|last=Attridge|first=Madeleine|last2=Creamer|first2=John|last3=Ramsden|first3=Michael|last4=Cannings-John|first4=Rebecca|last5=Hawthorne|first5=Kamila|date=2014-09-04|title=Culturally appropriate health education for people in ethnic minority groups with type 2 diabetes mellitus|url=|journal=Cochrane Database of Systematic Reviews|volume=|issue=9|pages=CD006424|doi=10.1002/14651858.CD006424.pub3|issn=1469-493X|pmid=25188210|via=}}</ref>。若輕度糖尿病患者的血糖無法藉由調整生活型態改善，則可能需要考慮配合藥物治療<ref name="Vij2010" />。目前仍尚無足夠證據說明調整生活型態對於患者死亡率的影響<ref name="Schellenberg2013" />。

===药物===
{{main|抗糖尿病药}}
[[File:Metformin_500mg_Tablets.jpg|thumb]]500mg片剂]]
目前有數类[[抗糖尿病药|抗糖尿病药]]，如雙胍類、[[磺酰脲类|磺酰脲类]]（sulfonylureas）、[[噻唑烷二酮類|噻唑烷二酮類]]（{{lang|en|thiazolidinedione}}）、[[胰高血糖素样肽-1类似物|GLP-1类似物]]、[[二肽基肽酶-4抑制剂|DPP-4抑制剂]]、[[钠-葡萄糖协同转运蛋白2抑制剂|SGLT2抑制剂]]等。遵照醫師建議使用藥物能有效控制病況，病患應定時用藥並定時回診追蹤，以降低血糖波動，達到最好控制效果。

* 雙胍類
** 由于有证据表明[[二甲双胍|二甲双胍]]（{{lang|en|metformin}}）可降低死亡率，因此通常将其作為第一线治疗药物<ref name="Ann2016" /><ref name="AFP09" /><ref>{{cite journal |last1=Palmer|first1=Suetonia C. |last2=Mavridis|first2=Dimitris |last3=Nicolucci|first3=Antonio |last4=Johnson|first4=David W. |last5=Tonelli|first5=Marcello |last6=Craig|first6=Jonathan C. |last7=Maggo|first7=Jasjot |last8=Gray|first8=Vanessa |last9=De Berardis|first9=Giorgia |last10=Ruospo|first10=Marinella |last11=Natale|first11=Patrizia |last12=Saglimbene|first12=Valeria |last13=Badve|first13=Sunil V. |last14=Cho|first14=Yeoungjee |last15=Nadeau-Fredette|first15=Annie-Claire |last16=Burke|first16=Michael |last17=Faruque|first17=Labib |last18=Lloyd|first18=Anita |last19=Ahmad|first19=Nasreen |last20=Liu|first20=Yuanchen |last21=Tiv|first21=Sophanny |last22=Wiebe|first22=Natasha |last23=Strippoli|first23=Giovanni F.M. |title=Comparison of Clinical Outcomes and Adverse Events Associated With Glucose-Lowering Drugs in Patients With Type 2 Diabetes|journal=JAMA: the Journal of the American Medical Association|date=2016-07-19|volume=316|issue=3|pages=313–24 |doi=10.1001/jama.2016.9400 |pmid=27434443 }}</ref>。然而目前有關此議結論仍有疑問<ref>{{cite journal|last=Boussageon|first=R|author2=Supper, I |author3=Bejan-Angoulvant, T |author4=Kellou, N |author5=Cucherat, M |author6=Boissel, JP |author7=Kassai, B |author8=Moreau, A |author9=Gueyffier, F |author10= Cornu, C |title=Reappraisal of metformin efficacy in the treatment of type 2 diabetes: a meta-analysis of randomised controlled trials|journal=PLOS Medicine|year=2012|volume=9|issue=4|pages=e1001204|pmid=22509138|doi=10.1371/journal.pmed.1001204|pmc=3323508|editor1-last=Groop|editor1-first=Leif}}</ref>，且並非所有第二線糖尿病患者都能一體適用，如有低血氧或是腎、肝、心臟疾病者，不建議使用二甲双胍<ref name="Vij2010" />。若[[二甲双胍|二甲双胍]]（{{lang|en|metformin}}）不足以控制病情，则可使用另一个类的口服制剂或注射胰島素辅助控制<ref name="ADA2015">{{cite journal|last1=Inzucchi|first1=SE|last2=Bergenstal|first2=RM|last3=Buse|first3=JB|last4=Diamant|first4=M|last5=Ferrannini|first5=E|last6=Nauck|first6=M|last7=Peters|first7=AL|last8=Tsapas|first8=A|last9=Wender|first9=R|last10=Matthews|first10=DR|title=Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes.|journal=Diabetologia|date=March 2015|volume=58|issue=3|pages=429–42|pmid=25583541|doi=10.1007/s00125-014-3460-0}}</ref>。
* [[磺酰脲类|磺酰脲类]]
** 用於2型糖尿病的抗糖尿病藥，主要作用是促進胰臟β細胞分泌胰島素。目前較常用的為[[格列美脲|格列美脲]]，為第二代[[噻唑烷二酮類|磺酰脲类]]藥物。<ref>{{Cite book|edition=8th ed|url=https://www.worldcat.org/oclc/659763408|publisher=McGraw-Hill Medical|date=2011|location=New York|isbn=0-07-170354-3|oclc=659763408|last=DiPiro, Joseph T.|title=Pharmacotherapy: a pathophysiologic approach}}</ref>
* [[噻唑烷二酮類|噻唑烷二酮類]]
** 用於2型糖尿病的抗糖尿病藥，主要作用是增進胰島素的感受性，改善血糖控制。<ref>{{Cite journal|title=Rosiglitazone for type 2 diabetes mellitus|url=http://doi.wiley.com/10.1002/14651858.CD006063.pub2|last=Richter|first=Bernd|last2=Bandeira-Echtler|first2=Elizabeth|date=2007-07-18|journal=Cochrane Database of Systematic Reviews|doi=10.1002/14651858.CD006063.pub2|editor-last=Cochrane Metabolic and Endocrine Disorders Group|language=en|last3=Bergerhoff|first3=Karla|last4=Clar|first4=Christine|last5=Ebrahim|first5=Susanne H}}</ref>目前有[[吡格列酮|吡格列酮]]（Pioglitazone）、[[罗格列酮|罗格列酮]]（Rosiglitazone）藥物。[[吡格列酮|吡格列酮]]（Pioglitazone）因有報導指出此藥物會增加膀胱癌的風險，法國跟德國已經暫時停止銷售這個藥物。<ref>{{Cite web|title=Diabetes Drug Actos Sales Suspended in France and Germany|url=http://www.huliq.com/3257/diabetes-drug-actos-sales-suspended-france-and-germany|accessdate=2020-05-04|date=2011-06-10|last=Santo|first=Michael|work=HULIQ|language=en|archive-date=2020-12-22|archive-url=https://web.archive.org/web/20201222192027/http://www.huliq.com/3257/diabetes-drug-actos-sales-suspended-france-and-germany|dead-url=no}}</ref>[[罗格列酮|罗格列酮]]（Rosiglitazone）過去曾有心臟副作用疑慮<ref>{{Cite web|title=European Medicines Agency starts review of rosiglitazone-containing medicines|url=https://www.ema.europa.eu/en/news/european-medicines-agency-starts-review-rosiglitazone-containing-medicines|accessdate=2020-05-04|date=2018-09-17|last=Anonymous|work=European Medicines Agency|language=en|archive-date=2021-01-05|archive-url=https://web.archive.org/web/20210105212448/https://www.ema.europa.eu/en/news/european-medicines-agency-starts-review-rosiglitazone-containing-medicines|dead-url=no}}</ref><ref>{{Cite journal|title=Risk of cardiovascular disease and all-cause mortality among diabetic patients prescribed rosiglitazone or pioglitazone: a meta-analysis of retrospective cohort studies|url=https://www.ncbi.nlm.nih.gov/pubmed/23217404|last=Chen|first=Xin|last2=Yang|first2=Li|date=2012-12|journal=Chinese Medical Journal|issue=23|volume=125|pages=4301–4306|issn=2542-5641|pmid=23217404|last3=Zhai|first3=Suo-di|access-date=2020-05-04|archive-date=2020-05-18|archive-url=https://web.archive.org/web/20200518014154/https://www.ncbi.nlm.nih.gov/pubmed/23217404|dead-url=no}}</ref><ref>{{cite journal|last=Chen|first=X|author2=Yang, L |author3=Zhai, SD |title=Risk of cardiovascular disease and all-cause mortality among diabetic patients prescribed rosiglitazone or pioglitazone: a meta-analysis of retrospective cohort studies|journal=Chinese Medical Journal|date=December 2012|volume=125|issue=23|pages=4301–06|pmid=23217404}}</ref>，2010年FDA曾限制使用條件，並要求藥商執行藥品風險評估暨管控計畫<ref>{{Cite journal|title=Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial|url=http://dx.doi.org/10.1016/s0140-6736(09)60953-3|last=Home|first=Philip D|last2=Pocock|first2=Stuart J|date=2009-06|journal=The Lancet|issue=9681|doi=10.1016/s0140-6736(09)60953-3|volume=373|pages=2125–2135|issn=0140-6736|last3=Beck-Nielsen|first3=Henning|last4=Curtis|first4=Paula S|last5=Gomis|first5=Ramon|last6=Hanefeld|first6=Markolf|last7=Jones|first7=Nigel P|last8=Komajda|first8=Michel|last9=McMurray|first9=John JV}}</ref><ref>{{Cite journal|title=FDA Drug Safety Communication: Ongoing review of Avandia (rosiglitazone) and cardiovascular safety|url=https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fda-drug-safety-communication-ongoing-review-avandia-rosiglitazone-and-cardiovascular-safety|last=Research|first=Center for Drug Evaluation and|date=2019-06-28|journal=FDA|language=en|access-date=2020-05-04|archive-date=2020-12-22|archive-url=https://web.archive.org/web/20201222192057/https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fda-drug-safety-communication-ongoing-review-avandia-rosiglitazone-and-cardiovascular-safety|dead-url=no}}</ref>，台灣亦跟進管制措施，直到2016年才解除限制。<ref>{{Cite web|title=經重新評估，含rosiglitazone成分藥品未顯示會增加心血管風險，停止執行風險評估暨管控計畫|url=https://www.fda.gov.tw/TC/newsContent.aspx?id=21647&chk=ffd7a698-1dbe-4bd5-aef1-1eac56f18fcc#.WGy3W_B97IV|accessdate=2020-05-04|date=2016-12-30|last=衛生福利部食品藥物管理署|work=衛生福利部食品藥物管理署|archive-date=2021-01-05|archive-url=https://web.archive.org/web/20210105212514/https://www.fda.gov.tw/TC/newsContent.aspx?id=21647&chk=ffd7a698-1dbe-4bd5-aef1-1eac56f18fcc#.WGy3W_B97IV|dead-url=no}}</ref>
*[[二肽基肽酶-4抑制剂|DPP-4抑制剂]]
**用於第2型糖尿病的抗糖尿病藥，為各類糖尿病藥物選擇中，安全性高、副作用最少的藥品類別<ref>{{Cite journal|title=Dipeptidyl peptidase-4 inhibitors and cardiovascular and renal disease in type 2 diabetes: What have we learned from the CARMELINA trial?|url=https://pubmed.ncbi.nlm.nih.gov/31018682|last=Hanssen|first=Nordin Mj|last2=Jandeleit-Dahm|first2=Karin Am|date=2019-07|journal=Diabetes & Vascular Disease Research|issue=4|doi=10.1177/1479164119842339|volume=16|pages=303–309|issn=1752-8984|pmc=6613297|pmid=31018682|access-date=2021-11-26|archive-date=2021-11-26|archive-url=https://web.archive.org/web/20211126074017/https://pubmed.ncbi.nlm.nih.gov/31018682/}}</ref><ref>{{Cite journal|title=Gastrointestinal Adverse Events of Dipeptidyl Peptidase 4 Inhibitors in Type 2 Diabetes: A Systematic Review and Network Meta-analysis|url=https://pubmed.ncbi.nlm.nih.gov/28827024|last=Wu|first=Shanshan|last2=Chai|first2=Sanbao|date=2017-09|journal=Clinical Therapeutics|issue=9|doi=10.1016/j.clinthera.2017.07.036|volume=39|pages=1780–1789.e33|issn=1879-114X|pmid=28827024|last3=Yang|first3=Jun|last4=Cai|first4=Ting|last5=Xu|first5=Yang|last6=Yang|first6=Zhirong|last7=Zhang|first7=Yuan|last8=Ji|first8=Linong|last9=Sun|first9=Feng|access-date=2021-11-26|archive-date=2021-11-26|archive-url=https://web.archive.org/web/20211126074017/https://pubmed.ncbi.nlm.nih.gov/28827024/}}</ref>。 主要是減少[[胰高血糖素|胰高血糖素]](升糖素)和降血糖，常見的有[[利格列汀|利拉利汀]]、[[沙格列汀|沙格列汀]]、[[维格列汀|維格列汀]]、[[西格列汀|西格列汀]]。[[利格列汀|利拉利汀]]是目前唯一一種非經腎臟排出體外的[[二肽基肽酶-4抑制剂|DPP-4抑制剂]]口服抗糖尿病藥<ref>{{Cite journal|title=The Metabolism and Disposition of the Oral Dipeptidyl Peptidase-4 Inhibitor, Linagliptin, in Humans|url=http://dx.doi.org/10.1124/dmd.109.031476|last=Blech|first=Stefan|last2=Ludwig-Schwellinger|first2=Eva|date=2010-01-19|journal=Drug Metabolism and Disposition|issue=4|doi=10.1124/dmd.109.031476|volume=38|pages=667–678|issn=0090-9556|last3=Gräfe-Mody|first3=Eva Ulrike|last4=Withopf|first4=Barbara|last5=Wagner|first5=Klaus}}</ref>，除患者本身對成份過敏外，利拉利汀並無禁忌症。研究指出，在不發生低血糖及體重增加的情況下，[[利格列汀|利拉利汀]]加上[[二甲双胍|二甲双胍]]效果優於[[馬爾胰|格列美脲]]搭配[[二甲双胍|二甲双胍]]。<ref>{{Cite journal|title=2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial|url=http://dx.doi.org/10.1016/s0140-6736(12)60691-6|last=Gallwitz|first=Baptist|last2=Rosenstock|first2=Julio|date=2012-08|journal=The Lancet|issue=9840|doi=10.1016/s0140-6736(12)60691-6|volume=380|pages=475–483|issn=0140-6736|last3=Rauch|first3=Thomas|last4=Bhattacharya|first4=Sudipta|last5=Patel|first5=Sanjay|last6=von Eynatten|first6=Maximilian|last7=Dugi|first7=Klaus A|last8=Woerle|first8=Hans-Juergen}}</ref>
*[[钠-葡萄糖协同转运蛋白2抑制剂|SGLT2抑制剂]]
**用於2型糖尿病的抗糖尿病藥，主要作用是抑制葡萄糖在腎臟的再吸收而使葡萄糖由尿液排除的抗糖尿病藥<ref>{{Cite journal|title=Empagliflozin in the treatment of type 2 diabetes: evidence to date|url=https://www.dovepress.com/empagliflozin-in-the-treatment-of-type-2-diabetes-evidence-to-date-peer-reviewed-article-DDDT|last=Shubrook|first=Jay|last2=Baradar-Bokaie|first2=Babak|date=2015-10|journal=Drug Design, Development and Therapy|doi=10.2147/DDDT.S69926|pages=5793|language=en|issn=1177-8881|last3=Adkins|first3=Sarah|access-date=2021-01-26|archive-date=2021-01-05|archive-url=https://web.archive.org/web/20210105212522/https://www.dovepress.com/empagliflozin-in-the-treatment-of-type-2-diabetes-evidence-to-date-peer-reviewed-article-DDDT|dead-url=no}}</ref>， SGLT2抑制劑可以降低血糖水平和體重，並且可以降低舒張壓與收縮壓。<ref>{{Cite journal|title=Efficacy, safety and regulatory status of SGLT2 inhibitors: focus on canagliflozin|url=http://www.nature.com/articles/nutd201440|last=Haas|first=B|last2=Eckstein|first2=N|date=2014-11|journal=Nutrition & Diabetes|issue=11|doi=10.1038/nutd.2014.40|volume=4|pages=e143–e143|language=en|issn=2044-4052|last3=Pfeifer|first3=V|last4=Mayer|first4=P|last5=Hass|first5=M D S|access-date=2021-01-26|archive-date=2021-01-05|archive-url=https://web.archive.org/web/20210105212555/https://www.nature.com/articles/nutd201440|dead-url=no}}</ref>常見藥物如[[达格列净|達格列淨]]、{{le|卡納格列淨|Canagliflozin}}、{{le|曲格列淨|Ertugliflozin}}、[[恩格列淨|恩格列淨]]，恩格列淨是首支SGLT2抑制劑類降糖藥有完成心血管預後研究的藥品，目前唯一口服降糖藥被研究証實有控糖、護心、保腎及減重等效果。<ref>{{Cite journal|title=Pharmacologic Management of Type 2 Diabetes: 2016 Interim Update|url=http://dx.doi.org/10.1016/j.jcjd.2016.02.006|date=2016-06|journal=Canadian Journal of Diabetes|issue=3|doi=10.1016/j.jcjd.2016.02.006|volume=40|pages=193–195|issn=1499-2671}}</ref>SGLT2抑制劑為第二型糖尿病的治療藥物，國際臨床研究結果顯示，[[恩格列淨|恩格列淨]](Empagliflozin)在管理[[心臟衰竭|心臟衰竭]]部分亦有成效，因此除糖尿病適應症外，同時具有心衰竭適應症，據2021年發表的國際臨床試驗證明，可以降低25%心衰竭住院或心血管死亡風險，並且延緩4倍腎絲球過濾率(eGFR)下降速率。SGLT2抑制劑同時被納入心臟衰竭的治療指引<ref>{{Cite journal|title=Correction to: Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction: The EMPEROR-Reduced Trial|url=http://dx.doi.org/10.1161/cir.0000000000000954|date=2021-01-26|journal=Circulation|issue=4|doi=10.1161/cir.0000000000000954|volume=143|issn=0009-7322}}</ref>。
*[[胰高血糖素样肽-1类似物|GLP-1类似物]](腸泌素)
**用於2型糖尿病的抗糖尿病藥，主要作用是提升胰島素分泌，並抑制餐後升糖素的分泌，達到降低血糖的效果。常見藥物有艾塞那肽、 利拉魯肽…等，需要用注射方式使用。<ref>{{Cite journal|title=Long-term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2-year results from the LEAD-2 study|url=http://dx.doi.org/10.1111/dom.12012|last=Nauck|first=M.|last2=Frid|first2=A.|date=2012-10-11|journal=Diabetes, Obesity and Metabolism|issue=3|doi=10.1111/dom.12012|volume=15|pages=204–212|issn=1462-8902|last3=Hermansen|first3=K.|last4=Thomsen|first4=A. B.|last5=During|first5=M.|last6=Shah|first6=N.|last7=Tankova|first7=T.|last8=Mitha|first8=I.|last9=Matthews|first9=D. R.}}</ref>
2018年醫學期刊The Lancet分析指出SGLT2抑制劑效果優於GLP-1與DDP-4可以降低心衰竭住院的風險、減少心肌梗塞、中風、心血管死亡等心血管不良總和事件，甚至可以減少45%腎臟病變風險。<ref>{{Cite journal|title=SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials|url=https://linkinghub.elsevier.com/retrieve/pii/S014067361832590X|last=Zelniker|first=Thomas A|last2=Wiviott|first2=Stephen D|date=2019-01|journal=The Lancet|issue=10166|doi=10.1016/S0140-6736(18)32590-X|volume=393|pages=31–39|language=en|last3=Raz|first3=Itamar|last4=Im|first4=Kyungah|last5=Goodrich|first5=Erica L|last6=Bonaca|first6=Marc P|last7=Mosenzon|first7=Ofri|last8=Kato|first8=Eri T|last9=Cahn|first9=Avivit|access-date=2021-03-19|archive-date=2020-10-07|archive-url=https://web.archive.org/web/20201007072304/https://linkinghub.elsevier.com/retrieve/pii/S014067361832590X}}</ref> SGLT2抑制劑[[達格列淨|達格列淨]]與[[恩格列淨|恩格列淨]]都經實驗證實可降低心臟衰竭病患因心血管因素而死亡或入院的風險<ref>{{Cite journal|title=SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials|url=https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31824-9/abstract|last=Zannad|first=Faiez|last2=Ferreira|first2=João Pedro|date=2020-09-19|journal=The Lancet|issue=10254|doi=10.1016/S0140-6736(20)31824-9|volume=396|pages=819–829|language=en|issn=0140-6736|pmid=32877652|last3=Pocock|first3=Stuart J.|last4=Anker|first4=Stefan D.|last5=Butler|first5=Javed|last6=Filippatos|first6=Gerasimos|last7=Brueckmann|first7=Martina|last8=Ofstad|first8=Anne Pernille|last9=Pfarr|first9=Egon}}</ref>，2020年SGLT2抑制劑也通過美國FDA認證可用於治療心臟衰竭<ref>{{Cite web|title=FDA approves new treatment for a type of heart failure|url=https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-type-heart-failure|access-date=2021-11-26|date=2020-05-22|last=Commissioner|first=Office of the|work=FDA|language=en|archive-date=2020-05-06|archive-url=https://web.archive.org/web/20200506004626/https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-type-heart-failure}}</ref>。

截至2015年為止研究指出，二甲雙胍(Metformin)因為其效果、價錢、安全性總和而言仍然是一線的最佳藥物，但因其副作用不建議腎功能衰竭者使用。<ref>{{Cite journal|title=ASHP Practitioner Recognition Program—2016 Fellows of the American Society of Health-System Pharmacists|url=http://dx.doi.org/10.2146/sp160001|date=2016-07-01|journal=American Journal of Health-System Pharmacy|issue=13|doi=10.2146/sp160001|volume=73|pages=1010–1010|issn=1079-2082}}</ref> 除一線用藥外，其餘糖尿病藥物的選擇基於降低血糖、最少副作用，以及患者的喜好、用藥習慣，各種患者自身疾病(如自身心血管疾病、慢性腎病)、用藥後不適應症(低血糖症)…等。<ref>{{Cite journal|title=Response to Comment on Inzucchi et al. Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach. Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2015;38:140–149|url=http://dx.doi.org/10.2337/dc15-1234|last=Herman|first=William H.|date=2015-08-20|journal=Diabetes Care|issue=9|doi=10.2337/dc15-1234|volume=38|pages=e143–e143|issn=0149-5992}}</ref>

2016年的研究指出糖尿病患者的血壓最好控制於140至150 mmHg之間<ref>{{cite journal|last1=Brunström|first1=Mattias|last2=Carlberg|first2=Bo|title=Effect of antihypertensive treatment at different blood pressure levels in patients with diabetes mellitus: systematic review and meta-analyses|journal=The BMJ|date=2016-02-24 |volume=352 |page=i717|doi=10.1136/bmj.i717 |pmid=26920333 |pmc=4770818 }}</ref>。

[[胰岛素|胰岛素]]可以單獨使用，也可以配合其他口服藥劑一起使用<ref name=AFP09/>，大多数人最初都无需注射[[胰岛素|胰岛素]]<ref name="Green2011"/>。当使用时，通常在夜间采用一种长效制剂，同时继续口服药物<ref name=Vij2010/><ref name=AFP09/>。劑量會過一段時間才起效，達到控制血糖的效果<ref name=AFP09/>。当夜间胰岛素不足，每日两次胰岛素可达到更好的控制<ref name=Vij2010/>。长效胰岛素，[[甘精胰岛素|甘精胰岛素]]（{{lang|en|glargine}}）和[[地特胰岛素|地特胰岛素]]效果及安全性相同<ref>{{Cite journal  | last1 = Swinnen | first1 = SG. | last2 = Simon | first2 = AC. | last3 = Holleman | first3 = F. | last4 = Hoekstra | first4 = JB. | last5 = Devries | first5 = JH. | title = Insulin detemir versus insulin glargine for type 2 diabetes mellitus | journal = Cochrane Database of Systematic Reviews | volume =  | issue = 7 | pages = CD006383 | year = 2011 | doi = 10.1002/14651858.CD006383.pub2 | pmid = 21735405| editor1-last = Simon| editor1-first = Airin CR }}</ref>，其效果並不優於[[中效胰岛素|中效胰岛素]]（NPH insulin），且價格又較貴，因此截至2010年的研究並無發現其實質效益<ref>{{cite journal|last=Waugh|first=N|author2=Cummins, E|author3=Royle, P|author4=Clar, C|author5=Marien, M|author6=Richter, B|author7=Philip, S|title=Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation|journal=Health Technology Assessment |location=Winchester, England|date=July 2010|volume=14|issue=36|pages=1–248|pmid=20646668|doi=10.3310/hta14360}}</ref>。对于怀孕的患者，胰岛素通常是治疗选择<ref name="Vij2010"/>。

過去謠傳補充[[维生素D|维生素D]]可預防糖尿病，根據2019年美國糖尿病學會年會最新研究指出，針對糖尿病前期的患者補充維生素D無法預防患者惡化成糖尿病，該研究同步發表在新英格蘭醫學期刊。<ref>{{Cite journal|title=Vitamin D Supplementation and Prevention of Type 2 Diabetes|url=http://www.nejm.org/doi/10.1056/NEJMoa1900906|last=Pittas|first=Anastassios G.|last2=Dawson-Hughes|first2=Bess|date=2019-08-08|journal=New England Journal of Medicine|issue=6|doi=10.1056/NEJMoa1900906|volume=381|pages=520–530|language=en|issn=0028-4793|last3=Sheehan|first3=Patricia|last4=Ware|first4=James H.|last5=Knowler|first5=William C.|last6=Aroda|first6=Vanita R.|last7=Brodsky|first7=Irwin|last8=Ceglia|first8=Lisa|last9=Chadha|first9=Chhavi|access-date=2020-05-18|archive-date=2021-01-05|archive-url=https://web.archive.org/web/20210105212532/https://www.nejm.org/doi/10.1056/NEJMoa1900906|dead-url=no}}</ref>

=== 複方藥物 ===
目前糖尿病口服藥物亦有複方藥物，如Glyxambi(糖順平)其限用於已接受過最大耐受劑量的[[二甲双胍|二甲雙胍]](Metformin)，且併用[[恩格列淨|恩格列淨]]（Empagliflozin, Jardiance，恩排糖） 或[[利拉利汀|利拉利汀]]（Linagliptin Trajenta，糖漸平） 治療，糖化血色素值(HbA1c)仍未低於8.5%者，亦有其他不同類型的複方藥物例如[[二肽基肽酶-4抑制剂|DPP-4抑制劑]]西格列汀(Sitagliptin, Januvia，佳糖維)與[[二甲双胍|二甲雙胍]](Metformin) 的複方藥物JANUMET（捷糖穩）、[[利格列汀|利拉利汀]]（Linagliptin, Trajenta，糖漸平）與[[二甲双胍|二甲雙胍]](Metformin) 的複方藥物Trajenta Duo（糖倍平）、[[维格列汀|維格列汀]]( Vildagliptin, Galvus，高糖優適) 與[[二甲双胍|二甲雙胍]](Metformin) 的複方藥物Galvus Met（高糖優美）。SGLT2抑制劑複方藥物也有[[恩格列淨|恩格列淨]]（Empagliflozin, Jardiance，恩排糖） 與[[二甲双胍|二甲雙胍]](Metformin) 的複方藥物 Jardiance Duo（恩美糖）、[[达格列净|達格列淨]](Dapagliflozin, Forxiga，福適佳) 與[[二甲双胍|二甲雙胍]](Metformin) 的複方藥物Xigduo XR（釋多糖）。複方藥物可提高患者服藥順從性，也可降低口服藥物的複雜程度，如Glyxambi(糖順平)綜合Empagliflozin 、Linagliptin優點，能降糖、降低體重、降低心血管疾病、保腎、不易低血糖多重功效。<ref>{{Cite journal|title=Glyxambi (Empagliflozin/Linagliptin): A Dual-Acting Oral Medication Approved for the Treatment of Patients with Type 2 Diabetes|url=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4665058/|last=Raedler|first=Lisa A.|date=2015-3|journal=American Health & Drug Benefits|issue=Spec Feature|volume=8|pages=171–175|issn=1942-2962|pmc=4665058|pmid=26629285|access-date=2021-03-19|archive-date=2022-04-23|archive-url=https://web.archive.org/web/20220423202452/https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4665058/}}</ref>

===外科手术===
对于超重的患者，[[代謝手術|代謝手術]]（减肥手术）是治疗糖尿病的有效措施<ref>{{cite journal |last=Picot |first=J|author2=Jones, J|author3=Colquitt, JL|author4=Gospodarevskaya, E|author5=Loveman, E|author6=Baxter, L|author7=Clegg, AJ|title=The clinical effectiveness and cost-effectiveness of bariatric (weight loss) surgery for obesity: a systematic review and economic evaluation |journal=Health Technology Assessment |location=Winchester, England|date=September 2009|volume=13 |issue=41 |pages= iii–iv, 1–190, 215–357|pmid=19726018 |doi=10.3310/hta13410}}</ref>。许多人手术后，能够维持正常的血糖水平并服用很少或根本不服用药物<ref>{{cite journal|last=Frachetti|first=KJ|author2=Goldfine, AB|title=Bariatric surgery for diabetes management|journal=Current Opinion in Endocrinology, Diabetes and Obesity |date=April 2009 |volume=16 |issue=2|pages=119–24 |pmid=19276974 |doi=10.1097/MED.0b013e32832912e7}}</ref>，且长期死亡率也會降低了<ref name=Schum2009>{{cite journal|last=Schulman|first=AP |author2=del Genio, F |author3=Sinha, N |author4=Rubino, F |title="Metabolic" surgery for treatment of type 2 diabetes mellitus|journal=Endocrine Practice |date=September–October 2009|volume=15|issue=6|pages=624–31 |pmid=19625245 |doi=10.4158/EP09170.RAR}}</ref>。不过仍存在低于1%的短期手术死亡风险<ref>{{cite journal |last=Colucci|first=RA|title=Bariatric surgery in patients with type 2 diabetes: a viable option |journal=Postgraduate Medicine|date=January 2011 |volume=123 |issue=1 |pages=24–33|pmid=21293081 |doi=10.3810/pgm.2011.01.2242}}</ref>。目前建議[[身高體重指數|身高體重指數]]（BMI）大於35的糖尿病患者進行代謝手術<ref name=":0">{{Cite journal|title=Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes|author=|url=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5557277/|last=Brito|first=Juan P.|last2=Montori|first2=Victor M.|date=2017-02-14|journal=JAMA|issue=6|doi=10.1001/jama.2016.20563|others=|year=|volume=317|page=|pages=635–636|issn=0098-7484|pmc=5557277|pmid=28196240|last3=Davis|first3=Andrew M.|access-date=2018-04-26|archive-date=2022-04-24|archive-url=https://web.archive.org/web/20220424031614/https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5557277/}}</ref><ref name=":1">{{Cite journal|title=Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes: A Joint Statement by International Diabetes Organizations|url=https://www.ncbi.nlm.nih.gov/pubmed?term=27568469|last=Rubino|first=Francesco|last2=Nathan|first2=David M.|date=July 2016|journal=Surgery for Obesity and Related Diseases: Official Journal of the American Society for Bariatric Surgery|issue=6|doi=10.1016/j.soard.2016.05.018|volume=12|pages=1144–1162|issn=1878-7533|pmid=27568469|last3=Eckel|first3=Robert H.|last4=Schauer|first4=Philip R.|last5=Alberti|first5=K. George M. M.|last6=Zimmet|first6=Paul Z.|last7=Del Prato|first7=Stefano|last8=Ji|first8=Linong|last9=Sadikot|first9=Shaukat M.|access-date=2018-04-26|archive-date=2020-05-18|archive-url=https://web.archive.org/web/20200518014232/https://www.ncbi.nlm.nih.gov/pubmed?term=27568469|dead-url=no}}</ref>。BMI介於30-35之間的若血糖控制不佳或有高度胰島素阻抗者，也建議進行<ref name=":0" /><ref name=":1" />。

==流行病学==
[[File:Global_Prevalence_of_Diabetes_(2014).png|thumb]]
2015年，全球2型糖尿病患者約有3.92亿人，占糖尿病患者的90%<ref name=Will2011/><ref name=GBD2015Pre/>，約相当于世界成人人口的6%<ref name=GBD2015Pre/>。糖尿病是[[已開發國家|已開發國家]]和[[发展中国家|发展中国家]]常见的疾病<ref name=Will2011/>。在经济欠发达地区仍然相當罕见<ref name="Green2011"/>。

糖尿病是台灣人十大死因之一，根據2021年衛福部統計，台灣現行糖尿病患人數約200多萬人，並以每年25,000名的速率持續增加中，對國人的健康影響不容小覷<ref>{{Cite web|title=衛生福利部國民健康署 - 糖尿病|url=https://www.hpa.gov.tw/Pages/List.aspx?nodeid=359|access-date=2021-10-25|archive-date=2022-03-03|archive-url=https://web.archive.org/web/20220303151454/https://www.hpa.gov.tw/Pages/List.aspx?nodeid=359}}</ref>。

女性在某些族裔中似乎罹病風險較高<ref name="Will2011" /><ref>{{cite journal |vauthors=Abate N, Chandalia M |title=Ethnicity and type 2 diabetes: focus on Asian Indians |journal=Journal of Diabetes and its Complications |volume=15 |issue=6 |pages=320–27 |year=2001 |pmid=11711326 |doi= 10.1016/S1056-8727(01)00161-1|url=}}</ref>，如[[南亚裔|南亚裔]]、{{le|太平洋岛民|Pacific Islander}}（{{lang|en|Pacific Islander}}）、[[拉美裔|拉美裔]]（{{lang|en|Latino}}），和[[美洲原住民|美洲原住民]]等族裔群体似乎有更高的患病风险<ref name="Vij2010" />。这可能是由于這些群体对西方的生活方式更为敏感<ref>{{cite journal|last1=Carulli|first1=L|last2=Rondinella|first2=S|last3=Lombardini|first3=S|last4=Canedi|first4=I|last5=Loria|first5=P|last6=Carulli|first6=N|title=Review article: diabetes, genetics and ethnicity|journal=Alimentary Pharmacology & Therapeutics|date=November 2005|volume=22 Suppl 2|pages=16–19|pmid=16225465|doi=10.1111/j.1365-2036.2005.02588.x}}</ref>。传统上，2型糖尿病歸類為成人疾病，然而随着{{le|儿童肥胖症|Childhood obesity|儿童肥胖率}}的增加，越来越多的儿童也被诊断罹患2型糖尿病<ref name="Will2011" />。美国青少年被诊断为2型糖尿病的频率与1型糖尿病同样频繁<ref name="Green2011" />。

糖尿病患者在1985年的数量估计在3000万，在1995年增至1.36亿，2005年增加至2.17亿<ref name=Epi2006/>。增加的原因主要是全球人口老龄化、运动减少，和肥胖率增加<ref name="Epi2006"/>。至2000年為止，糖尿病患者数最多的五个国家是印度（3170万）、中国（2080万）、美国（1770万）、印度尼西亚（840万）和日本（680万）<ref name = "Wild 2004">{{cite journal |vauthors=Wild S, Roglic G, Green A, Sicree R, King H |title=Global prevalence of diabetes: estimates for the year 2000 and projections for 2030 |journal=Diabetes Care |volume=27 |issue=5 |pages=1047–53 |date=May 2004 |pmid=15111519|doi= 10.2337/diacare.27.5.1047|url=}}</ref>。糖尿病被[[世界卫生组织|世界卫生组织]]确认为一种全球性[[流行病|流行病]]<ref name=WHO2015/>。

==历史==
糖尿病是最早被記錄的疾病之一<ref name=Rip2011/>，早在公元前约1500年的埃及手稿将其称为“尿液過多”<ref name="History2010"/>。據信首个有记载的病例被认为是1型糖尿病<ref name=History2010>{{cite book |last1=Zajac |first1=Jacek |last2=Shrestha |first2=Anil |last3=Patel |first3=Parini |last4=Poretsky |first4=Leonid |chapter=The Main Events in the History of Diabetes Mellitus |editor-last=Poretsky |editor-first=Leonid |title=Principles of diabetes mellitus|year=2009|publisher=Springer|location=New York|isbn=978-0-387-09840-1|pages=[https://books.google.com/books?id=i0qojvF1SpUC&pg=PA3 3]–[https://books.google.com/books?id=i0qojvF1SpUC&lpg=PA3&pg=PA16 16] |edition=2nd |oclc=663097550 }}</ref>。同時期，古印度的医生在同期也發現了该病，由於患者的尿液會引來螞蟻，因此將其歸稱为“蜜糖尿”（{{lang|en|''madhumeha''}}）<ref name="History2010"/>。而現今所使用的醫學術語「{{lang|en|diabetes}}」一詞源自希臘文的「siphon」（虹吸管），意思是「在彎管中流動」，描述其多尿的症狀。該词是由希腊人[[孟菲斯_(埃及)|孟菲斯]]之{{link-en|阿波罗尼奥斯 (医生)|Apollonius (physician)|阿波罗尼奥斯}}（{{lang|en|Apollonius of Memphis}}）在公元前230年首次使用<ref name="History2010"/>。根據[[蓋倫|蓋倫]]的描述，在[[罗马帝国|罗马帝国]]时期，该病可能属罕见病，在其生涯中僅見兩例<ref name=History2010/>。

公元400-500年，印度医生[[妙聞|妙聞]]和{{le|揭羅迦|Charaka}}首次将-{zh-tw:第一型; zh-hk:一型; zh-cn:1型;}-和-{zh-tw:第二型; zh-hk:二型; zh-cn:2型;}-糖尿病区分开来，认为-{zh-tw:第一型; zh-hk:一型; zh-cn:1型;}-与青年有关，而-{zh-tw:第二型; zh-hk:二型; zh-cn:2型;}-与體重過重有关<ref name="History2010"/>。“{{lang|en|mellitus}}”一词由英国人约翰·罗尔（{{lang|en|John Rolle}}）于1700年代末期首次使用，用于与频繁排尿的[[尿崩症|尿崩症]]相区分<ref name="History2010"/>。雖然有關糖尿病的紀述相當古老，但该病一直没有有效的治疗。直到20世纪初，加拿大人[[弗雷德里克·班廷|弗雷德里克·班廷]]和[[查尔斯·贝斯特|查尔斯·贝斯特]]在1921年和1922年发现胰岛素<ref name="History2010"/>。随后又在1940年代开发出长效NPH胰岛素<ref name="History2010"/>。

==备注==
{{NoteFoot}}

==参考文献==
{{reflist|30em}}

;附注
{{reflist|group=注}}

==外部链接==
{{Sister project links}}
*{{dmoz|Health/Conditions_and_Diseases/Endocrine_Disorders/Pancreas/Diabetes/Type_2}}
*[http://www.cdc.gov/diabetes/ 美国疾病控制中心（内分泌病理）] {{Wayback|url=http://www.cdc.gov/diabetes/ |date=20100803093606 }}
*[https://www.tade.org.tw/ 社團法人中華民國糖尿病衛教學會] {{Wayback|url=https://www.tade.org.tw/ |date=20220501064443 }}
*[http://www.endo-dm.org.tw/ 中華民國內分泌暨糖尿病學會] {{Wayback|url=http://www.endo-dm.org.tw/ |date=20220417232104 }}
*[http://www.endo-dm.org.tw/dia/ 中華民國糖尿病學會] {{Wayback|url=http://www.endo-dm.org.tw/dia/ |date=20220419181047 }} 

{{Diabetes}}
{{Amyloidosis}}
{{Endocrine pathology}}

[[Category:老化相关疾病|Category:老化相关疾病]]
[[Category:糖尿病|Category:糖尿病]]
[[Category:與肥胖有關的醫學症狀|Category:與肥胖有關的醫學症狀]]
{{Good article}}